Changing the landscape of cancer

LLS FUNDED 268 academic research grants around the world in 2016.

Last year, our Information Resource Center conducted 6,000 SEARCHES FOR CLINICAL TRIALS for blood cancer patients.
President and Chairman’s Message

The fight against cancer is at a unique moment in time. While it is never a good time to get cancer, it is a phenomenal time to be fighting it. The Leukemia & Lymphoma Society (LLS) is on the frontlines.
The combination of new genomic technology, an even deeper understanding of the biology of cancer and the output of new drugs from the pharmaceutical industry make this an extremely exciting time in the field of blood cancer research and treatment.

We saw remarkable progress in treatments for patients with myeloma, chronic lymphocytic leukemia and Hodgkin lymphoma in Fiscal Year 2016, and emerging approaches in immunotherapy and precision medicine continue to show great promise. We entered into new partnerships with biotechnology companies advancing promising new therapies for blood cancer patients, and we played an integral role in supporting Vice President Joe Biden’s Cancer Moonshot. LLS is uniquely positioned to lead the charge to find cures and ensure access to treatments for patients with blood cancers.

In addition to our dedicated staff, none of this would be possible without the tens of thousands of volunteers across the country who work every day for patients. It’s never been truer – we are a volunteer led, staff driven organization. And we are laser-focused on growth to drive revenue to fuel our mission.

Along with passionate individual and corporate donors, our fundraising campaigns are the driving force moving our mission forward. We are enhancing these iconic programs to capture the imagination of a new generation of donors and participants, and are tapping into the creativity and passion of countless volunteers to elevate awareness of our mission and enhance our ability to stand out in a crowded field of cancer charities and other nonprofits. LLS plays key role in the cancer arena through our ability to convene key stakeholders, including regulatory decision-makers, patients, researchers, top cancer centers, pharmaceutical companies, providers, payors and policy makers. We support breakthrough research and impactful policy initiatives, and provide meaningful patient support and education. LLS is better equipped than ever to make someday today for the 1.2 million people in the United States living with, or in remission from, a blood cancer.

Despite progress we still have much work to do to find cures and help patients access lifesaving treatments. With your continued support we will continue to move closer to cures, changing the landscape of cancer forever.

Louis J. DeGennaro, PhD
President and CEO

James H. Davis, PhD, JD
Chairman of the Board
Fundraising campaigns: The fuel making someday today

Volunteers fuel our mission: As a nonprofit, LLS relies on the generosity of individuals, corporations and foundations.

650,000+ participants have raised funds through Team In Training marathons, triathlons, cycling & hiking events.

860 participants competed for the Man & Woman of the Year title in 2016.
Families and communities honored blood cancer survivors, as well as those lost to the diseases, by taking part in nearly 200 Light The Night Walks across North America in Fall 2015. Sponsors as well as friends, family and corporate teams raised more than $61 million for blood cancer research. For the third year, actor and musician Charles Esten volunteered his time as the National Light The Night Walk honorary chair in recognition of the impact LLS research has had on pediatric cancer care.

Team In Training®

Team In Training (TNT), the world's largest and most successful endurance sports training program for charity, is raising the bar on its efforts to create a world without blood cancers. Thousands of “teammates” volunteered for TNT in Fiscal Year 2016 to inspire personal discovery and help turn training into treatments for blood cancer patients. Funds raised through this premier charity sports program help LLS lead the way in finding therapies that are saving lives today. Teammates can choose to run or walk a marathon or half marathon, swim, bike and run a triathlon, embark on a century bike ride (100 miles) or set out on a hiking adventure. They become part of a supportive team and benefit from high-caliber coaching that helps achieve fitness goals. The program raised $33.7 million in Fiscal Year 2016, and has raised more than $1.5 billion over the past 28 years.

Student Series™

In Fiscal Year 2016, volunteers in the combined Student Series: Pennies for Patients, Pasta for Pennies presented by Olive Garden, and Hop for Leukemia raised a total of $26.5 million. Nearly 13 million students in 25,000 schools learned about service, leadership and philanthropy, and saw firsthand how their involvement made a difference in helping save the lives of blood cancer patients.

Man & Woman of the Year

The 2016 Man & Woman of the Year set another campaign record. For 10 weeks, in more than 80 cities across the country, 860 dedicated community leaders with more than 6,200 registered team members volunteered their time and energy to compete locally to win the prestigious national title of LLS’s Man & Woman of the Year. Candidates raised $38 million, surpassing last year’s total by more than $5 million.

Amanda Bush of Texas, daughter-in-law of Jeb Bush, and Jim Chrisman of Colorado, were the leading 2016 fundraisers, with $489,417 and $419,399 raised, respectively. Notably, Amanda Bush, who set a new record for the highest amount raised by a candidate, ran in memory of Robin Bush, the daughter of former President George H.W. Bush and First Lady Barbara Bush. Robin was just 3 years old when she died of leukemia in 1953.

This year’s All Star Alumni winners were Tam Driscoll of Portland, OR, and Joseph Vicari of Detroit, MI, raising nearly $400,000 combined.
Leukemia Cup Regatta

The Fiscal Year 2016 Leukemia Cup Regatta campaign grossed nearly $3.9 million, a 5% increase over the prior fiscal year. More than 11,000 sailors, powerboaters and standup paddlers, and the general public volunteered in Leukemia Cup activities. Sailing legend Gary Jobson, a lymphoma survivor, continued his service as the national chair of the Leukemia Cup Regatta series, which consists of events throughout the United States and Canada. More than $58 million has been raised through the Leukemia Cup Regatta series since its start 30 years ago at the Pine Harbor Yacht Club in Birmingham, AL (now Birmingham Sailing Club), when the area sailing community decided to hold a race in memory of Stan Wrobel, a local sailor who lost his life to leukemia.

Partnerships

United Food and Commercial Workers Union (UFCW)

The UFCW has been a powerful voice for LLS for 33 years, with its members raising more than $80 million for LLS in that time span. In Fiscal Year 2016 alone, the UFCW generated nearly $2 million in the United States, and more than $2.4 million in Canada, through a variety of fundraising efforts ranging from golf outings and banquets to auctions and dinners. Thousands of UFCW staff and members volunteered in this year’s Light The Night Walk, and they contributed more than $250,000 to that effort. In Canada, the extraordinary one-day “bottle drive” raised more than $1.6 million.

Burlington

Burlington Stores partnered with LLS’s Light The Night Walk campaign for the 14th consecutive year to help support blood cancer research and advance new treatments for cures. The off-price retailer – LLS’s largest national partner – encouraged customers to donate to the cause at check-out and raised more than $3.3 million. That brings Burlington’s grand total collection since the partnership’s inception to well over $25 million.

Walgreens

LLS launched an innovative collaboration with Walgreens Specialty Pharmacy to create new approaches to support cancer patients in their communities, provide educational tools and resources for enhanced patient support and implement a pharmacist education and training program. Walgreens has been a longstanding supporter of LLS and will accelerate community engagement and corporate support for the Light The Night Walk.

runDisney

In January 2016 Team In Training and runDisney celebrated our 20th Anniversary at the Walt Disney World® Marathon in Orlando, FL. Our partnership over the past 20 years has resulted in more than 28,800 teammates participating and more than $82.5 million raised at Walt Disney World® Marathon Weekend! When we tally the total mission impact at all runDisney events, it is over 34,000 teammates and more than $98 million raised for LLS.

Bike the West

Since 1997 when we first packed up bikes in cardboard boxes to ship to South Lake Tahoe, more than 24,000 Team In Training cyclists have enjoyed America’s Most Beautiful Bike Ride. June 2016 saw Team In Training and Bike the West celebrate our 20th year participating in this event and our fundraising total eclipse $94 million raised for LLS.
Donor Development

Charitable donations fuel every aspect of the LLS mission. With direct gifts that totaled $35.6 million, donors enthusiastically donated resources for research and patient programs. Highlights included a $1 million gift from Drenda Vijuk in memory of her husband, Joe, a chronic myeloid leukemia patient. Also, the Harry T. Mangurian, Jr. Foundation made a second multi-million dollar commitment to acute myeloid leukemia (AML) research, ensuring its progression to the clinical trial phase. Other donors who directly supported LLS’s Therapy Acceleration Program® (TAP), a strategic initiative to invest directly in biotechnology companies, were gratified by significantly increased survival data from a Phase 3 trial by TAP partner Celator Pharmaceuticals.

LLS gratefully acknowledges all donors who fund the mission and proudly lists gifts of $10,000 or more within the pages of this report. We also honor the memories of thoughtful people who use lifetime assets to make their largest gifts through bequests or beneficiary designations in retirement plans. Nearly $8 million was received in this manner during the year. Giving also includes our Blood Cancer Awareness Month activities and online fundraising.

Blood Cancer Awareness Month

LLS launched a comprehensive marketing and communications campaign in September 2015 for Blood Cancer Awareness Month. The effort involved printed materials, website pages, digital and social media, email support and public relations across national and local markets, and was further boosted by a “Turn it Red” campaign wherein more than 40 landmarks across the nation and internationally turned their lights red throughout the month.

Online Fundraising

Online fundraising continues to increase in importance to LLS, and is driven largely by our digital marketing efforts. Specifically, we take advantage of sophisticated digital targeting capabilities to recruit participants to join our fundraising campaigns, support them in their own fundraising efforts, keep them engaged and informed post-event, and encourage their ongoing participation. We also use these channels to drive direct donations, particularly during seasonally driven opportunities such as Blood Cancer Awareness Month (September), Giving Tuesday (first Tuesday post-Thanksgiving) and December when all charitable giving peaks.
Research that is changing the landscape of cancer

The LLS research agenda is focused on finding cures and driving research in areas of unmet medical need.

LLS has invested more than $1 billion in research to advance cancer treatments and cures.
Research Spending

LLS's total research funding for Fiscal Year 2016 was $49.3 million across academic grants and the Therapy Acceleration Program (TAP). The majority of our research commitments are multi-year and reflected below is the fiscal spending.

Academic Grants
LLS's academic research grant funding in Fiscal Year 2016 was $40.3 million, with 268 grants funded during the year. LLS announced a commitment to invest $28.6 million in new multi-year grants, with the first year of those grants supported by the Fiscal Year 2016 budget for $11.49 million. In addition to seeking cures and better treatments for patients, cancer researchers play critical roles with LLS, volunteering their time on boards to review research applications for grants and serving as panelists for our research symposia and educational programs.

Therapy Acceleration Program
LLS supported 22 projects through its Therapy Acceleration Program (TAP), a strategic initiative through which we build business alliances and collaborations with biotechnology companies and academic researchers to speed the development of new therapies and diagnostics. In Fiscal Year 2016 $9.3 million was invested in new and on-going TAP commitments. Several of our TAP partners celebrated significant milestones in Fiscal Year 2016.

Stemline Therapeutics
TAP partner Stemline Therapeutics reported promising results in 2016 for a therapy to treat a rare blood cancer, blastic plasmacytoid dendritic cell neoplasm, which has no approved standard of care. Stemline reported during the American Society of Clinical Oncology meeting that 89% of patients in a clinical trial had an overall response to its drug, SL-401. The drug, which targets the CD123 protein present on a wide range of blood cancers, is also being tested in AML and multiple myeloma (MM).

Celator Pharmaceuticals
LLS's TAP partner Celator Pharmaceuticals (recently acquired by Jazz Pharmaceuticals) announced positive data in Fiscal Year 2016 for its investigational therapy CPX-351 (Vyxeos™) from an LLS-supported Phase 3 clinical trial. Celator's innovative formulation of two standard chemotherapy drugs performed significantly better than the standard therapy, including a statistically significant improvement in overall survival in the clinical trial for newly diagnosed patients, age 60-75, with high-risk (secondary) AML. Based on the outcome of the trial, a new drug application is anticipated some time in Fiscal Year 2017. If approved by the FDA, this would mark the first time that LLS's direct investment in a biotechnology company has enabled a newly approved therapy to reach thousands of patients, a significant achievement for LLS's venture philanthropy initiative.
Valor Biotherapeutics

In Fiscal Year 2016 LLS’s TAP partner Valor Biotherapeutics initiated its first-in-human, Phase 1 clinical study of IGN002, a novel investigational treatment for non-Hodgkin lymphoma (NHL). IGN002 is a therapy combining an antibody and a cytotoxic agent to target the CD20 protein in lymphoma patients. LLS has been supporting Valor’s pre-clinical development and manufacturing of the drug over the past two years.

Kiadis Pharma

LLS initiated a new partnership with Kiadis Pharma through an equity investment into the development of ATIR101™, an innovative T-cell immunotherapy for blood cancers. This partnership was further strengthened by a second equity investment in July. This TAP investment supports Kiadis’ second ongoing Phase 2 trial in leukemia patients, and will be continued into a Phase 3 pivotal study. ATIR101 is a therapy, for adult AML and acute lymphoblastic leukemia (ALL) patients undergoing a stem cell transplantation procedure using donor cells from a half-matched donor who is related to the patient. Stem cell transplantation is one of the most effective curative treatments for blood cancer patients, but it comes with great risk of life-threatening infection and graft versus host disease (GVHD). Kiadis Pharma’s ATIR101™ shows promise in fighting these infections by boosting the patient’s immune system while also reducing GVHD.

Beat AML

More than 20,000 patients a year are diagnosed with AML and 10,000 will die annually. LLS continued to lead the offensive against AML in Fiscal Year 2016. We convened an unprecedented collaboration of academic researchers, pharmaceutical companies, a genomic provider, and the Food & Drug Administration to lay the groundwork for a multi-site, multi-treatment arm AML Master Trial. We are set to begin enrolling patients in Fiscal Year 2017. The groundbreaking Beat AML Master Trial will employ advanced genomic technology to enable a precision medicine approach. The goal is to rapidly identify patients’ genetic mutations so the patient can be directed to the appropriate trial testing a novel targeted therapy most likely to be effective for their genetic profile. The trial is expected to improve outcomes for AML patients as there has been no change in the standard of care for this patient population in 40 years.
The 57th American Society of Hematology (ASH) Annual Meeting brought tens of thousands of researchers to Orlando to present data from thousands of clinical trials, with encouraging results for cutting-edge approaches to targeted therapy and immunotherapy. Chimeric antigen receptor therapy (CAR-T), one of a number of methods under development to harness the body's immune system to kill cancer cells, continued to garner attention.

LLS-funded researchers were well-represented at the meeting. Researchers from University of Pennsylvania, where LLS has been supporting a CAR-T program for two decades, presented encouraging results in various studies for patients with lymphoma, ALL and CLL.

CLL afflicts approximately 19,000 new patients per year in the United States. Over the past three years, LLS investment in new research and therapies for CLL has dramatically paid off. Our investment helped advance new therapies approved by the FDA in 2016 for CLL treatment, including ibrutinib and venetoclax. In particular, in 2016, an LLS Specialized Center of Research (SCOR) team, headed by Thomas Kipps, MD, PhD, at University of California San Diego presented data at the ASH meeting showing ibrutinib was superior to a standard chemotherapy in treating CLL patients. These findings contributed to the FDA approval of ibrutinib as a first-line treatment for newly diagnosed CLL patients in place of chemotherapy. In addition, The Ohio State University blood cancer scientist John Byrd, MD, whose work LLS has supported for almost two decades, presented several new CLL studies at the ASH meeting. His LLS-supported work led to the original approval of ibrutinib for CLL in 2014. At the ASH meeting he presented data on another investigational drug that targets BTK, the same protein that is targeted by ibrutinib, and appears to be even more effective.

Another study by an LLS SCOR team at the Walter & Eliza Hall Institute of Medical Research (WEHI) in Australia showed that 92% of the study’s relapsed CLL patients responded to venetoclax, which targets the BCL-2 protein in cancer cells. BCL-2 controls the life or death of a cell. Venetoclax was FDA approved later in Fiscal Year 2016 for a subset of patients with a high-risk form of CLL. Since 2002, LLS has supported more than $15 million in research leading to the development of this drug through its collaborative SCOR program.
**LLS’s Satellite Symposium**

LLS sponsored a satellite symposium in Orlando in advance of the ASH meeting titled “Molecularly Targeted Therapies for Hematologic Malignancies.”

Five prominent blood cancer experts volunteered their time as panelists, highlighting efforts to develop precisely targeted therapies that go after the tumor cells while sparing the healthy cells. More than 600 attendees learned the latest advances in AML, T-cell acute lymphoblastic leukemia (T-ALL), CLL and MM.

**A Special Roundtable Discussion**

LLS brought together a world-renowned panel of thought leaders from research, clinical practice, policymaking, the pharmaceutical industry and patient advocacy to discuss the latest advances in blood cancer research and treatment, cost of care and patient advocacy and policy. The signature event, titled “Blood Cancers: Standards of Care, Gateways to Cancer Cures,” was held in New York City and addressed collaboration, access to treatments, venture philanthropy, precision medicine and AML, targeted therapies and the promise of immunotherapy.

**Supporting the Moonshot**

LLS is actively supporting Vice President Biden’s Cancer Moonshot initiative in an effort to accelerate cancer cures.

Dr. DeGennaro was one of many leaders representing the cancer community in Biden’s daylong National Cancer Moonshot Summit at Howard University in Washington, D.C., on June 29. The group discussed new ideas and collaborations, and Dr. DeGennaro led a breakout session, “Advancing Research Discoveries and Catalyzing Scientific Breakthroughs.”

Simultaneously, LLS hosted the “LLS Cancer Moonshot Town Hall,” a national webcast to more than 900 participants, to show how the organization’s work is aligned with that of the Moonshot initiative.

Dr. DeGennaro also joined an expert panel at the annual Milken Institute Global Conference, “Promise of the Cancer Moonshot,” to share LLS’s perspective about what needs to be done to move this effort forward.
Research Advances Highlighted in Media Tour

The American Society of Clinical Oncology (ASCO) meeting took place in Chicago June 3-7. As the world’s largest cancer conference, it affords an opportunity for researchers from around the world to share their latest data from cancer clinical trials. To kick off the meeting, LLS President and CEO Louis J. DeGennaro was joined by Gail Roboz, MD, Professor of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, for a satellite media tour in New York City, to address the latest research news coming out of the annual ASCO meeting. They participated in interviews with 25 TV and radio stations across the country. Dr. DeGennaro discussed LLS’s role in advancing new and better treatments and ensuring access, and Dr. Roboz shared her experience as an expert in AML.

Patient and Professional Education

In 2016, LLS’s Patient Access department delivered 10 live disease-focused webinars nationally, with more than 3,200 participants. Our patient and professional videos and virtual lectures have been downloaded more than 20,000 times, and more than 600,000 disease and support booklets were distributed.

Additionally, LLS chapters hosted 168 local community-based education programs for patients, caregivers and healthcare professionals, and five local interactive grand rounds for physicians. A symposium focused on clinical trials and CAR-T therapy was held at the annual Oncology Nursing Society conference with more than 600 attendees.
Working to ensure access to care for all blood cancer patients

The goal of The Leukemia & Lymphoma Society is to reach patients soon after diagnosis to provide support, disease and treatment information, and access to quality care. LLS continues to be a leader in the delivery of blood cancer education and in enhancing patient access to treatments.

$40+ MILLION provided in co-pay assistance.
**Information Resource Center**

Callers to LLS’s Information Resource Center (IRC) speak one-on-one with master’s degree level healthcare professionals who help them deal with the challenges of a blood cancer diagnosis. Information specialists offer accurate, current disease treatment and support information, and they guide patients through the psychosocial and financial challenges of blood cancer treatment and survivorship. More than 26,000 inquiries were handled by the IRC in Fiscal Year 2016. The IRC’s clinical trial navigator assisted 167 patients with complex clinical trial searches, and 49% enrolled in a trial. Information specialists can be reached at (800) 955-4572 between 9 a.m. and 9 p.m. ET Monday through Friday.

**Patti Robinson Kaufmann First Connection Program**

The *Patti Robinson Kaufmann First Connection Program* helps newly diagnosed patients cope with their disease by matching them with trained volunteers who have also been touched firsthand by a blood cancer. The peer-to-peer program successfully matched more than 700 patients with volunteers in Fiscal Year 2016.

**Co-Pay Assistance**

LLS’s Co-Pay Assistance Program helps eligible blood cancer patients pay for their prescription drug co-pays and health insurance premiums. LLS provided more than $40 million to patients in Fiscal Year 2016 through this program.

**LLS Community Launch**

LLS’s mission includes searching for the best outcomes for patients and in that regard has committed to building a national database of all blood cancer patients to compare and contrast treatment experiences. Toward that endeavor, the first phase of this project – The LLS Community – was launched in Fiscal Year 2016. This online site has the familiar look and feel of modern social media sites, but offers an extended conversation and a sense of community. Visitors set up a free account and those recently diagnosed or living with a blood cancer fill out a profile about their diagnosis and treatment. Caregivers as well as supporters are invited to join. In return, all are provided disease-specific information, news and supportive discussion groups as well as inclusion in periodic research surveys. More than 2,500 have joined since the launch in 2016.

**Laws to Make Oral Drugs More Affordable**

The governors of both Alaska and Pennsylvania signed oral parity laws in 2016, bringing the number of supporting states to 42 plus the District of Columbia. The laws extend a critically important financial protection to thousands of patients living with cancer by ensuring that medications taken orally (self-administered) will receive equitable healthcare coverage to those who receive treatment via infusion or injection in a clinical setting. LLS has been a key player in efforts to pass oral parity laws, leading the coalition in Pennsylvania for the past seven years, growing it to more than 20 patient organizations, healthcare provider associations and the most prominent academic health centers in the state. Volunteer patient advocates played critical roles in helping to get these laws passed, testifying before legislators and participating in letter-writing campaigns.
LLS is the voice of all blood cancer patients and is dedicated to removing barriers to care.
Bringing the Patient Voice into Drug Development

LLS brought a delegation of 15 AML survivors, seven caregivers and other LLS leaders to Washington, D.C., in April to share personal experiences with the FDA and discuss plans for a research study to learn what patients and caregivers are looking for in new treatments. The survivors and caregivers engaged in a roundtable dialogue with Richard Pazdur, MD, FDA director of the Office of Oncology Drug Products, and 20 of his staff and colleagues.

LLS is collaborating with The Johns Hopkins School of Public Health to develop an innovative research study, “Quantifying Patient and Caregiver Preferences for the Treatment of AML,” designed to understand patient experiences and expectations, their AML-related worries, and their preferences for the benefits and risks of treatment. A pilot study was conducted in Fiscal Year 2016 and will be expanded in Fiscal Year 2017 to between 100 and 200 people. Ultimately, LLS’s hope is that the results will be used to help ensure that both the FDA and drug manufacturers better understand patients’ and caregivers’ perspectives and include their preferences in the drug development process.

LLS Volunteer Engagement Initiative

It has never been truer, or more necessary, for LLS to fulfill its vision as a volunteer led, staff driven organization. Throughout 2016, we have stepped up efforts to empower passionate leaders to help drive recruitment, engagement and growth of all of our campaigns. Volunteers also play critical roles in our patient access and policy initiatives.

They are extraordinary individuals, companies, clubs and organizations, all dedicated to helping LLS advance its mission. Our volunteers are at the heart of everything we do at LLS. They give their time and talent to make significant differences in the lives of patients and their families in so many ways. Some have achieved remarkable fundraising goals. Others dedicate their services to providing support and expertise for the patients we serve. Some have contributed by helping to create a national program or by helping to elevate LLS’s public profile.
Volunteers

LLS Volunteer Engagement Initiative

LLS implemented the 2016 NATIONAL RECOGNITION & AWARDS PROGRAM

Highlighting the significant contributions of the volunteers who impact our organization and patients.
Throughout 2016 we developed and implemented robust volunteer engagement strategies across our mission and campaign programs to strengthen our efforts to reach and help more patients and support more revenue channels.

- As a critical example, we created a new Patient Access Volunteer Development Program designed to increase our ability to reach and support patients and caregivers soon after diagnosis, and to broaden volunteer engagement in the work of patient access and the organization as a whole. With this program, it is our goal to generate heightened community awareness of LLS and to connect more patients and caregivers with LLS resources so that anyone facing a blood cancer has access to high quality care and can be strengthened by the experiences of others.

- Our volunteer advocates played key roles in our efforts to advance laws and policies to ensure patients have greater access to therapies by testifying in person before government officials and sharing their stories in person, through social media, and letter-writing campaigns.

Importantly, we implemented a National Recognition and Awards program in 2016 to highlight the significant contributions of the volunteers who impact our organization and the patients we help in so many ways every day. Throughout the year, we took opportunities to recognize these invaluable volunteers and on the following pages you will find each volunteer who was recognized in 2016.
Recognition of the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and treasure and have made a significant difference in the lives of so many. To find out more about our awards program, please go to https://www.lls.org/national-awards-nomination.

Congratulations to all the 2016 awardees!
2016 National Media Awards Recipients

Recipients have a record of excellence in promotional support/fundraising, as well as educating and informing the public of the LLS organization and its mission.

Digital
Kevin Mumprey and Rene Michele
MVP Productions
Mississippi/Louisiana Chapter

Print
Albany Business Review
Upstate New York & Vermont Chapter

APG Media of Chesapeake LLC
Maryland Chapter

Jennifer Bertetto
TRIB Total Media
Western Pennsylvania & West Virginia Chapter

Boston Magazine
Massachusetts Chapter

Marcus Fuller
St. Paul Pioneer Press
Minnesota Chapter

GFR Media/El Nuevo Dia
Southern Florida & Puerto Rico Chapter

Dustin Holt
APG Media of Chesapeake LLC
Maryland Chapter

Leah Palone
Boston Magazine
Massachusetts Chapter

San Diego Union Tribune
San Diego & Hawaii Chapter

St. Paul Pioneer Press
Minnesota Chapter

TRIB Total Media
Western Pennsylvania & West Virginia Chapter

Radio
Kristi Carson
Emmis Communication
Gateway Chapter

Reggie Dee
X102.3 FM
Palm Beach Area Chapter

Emmis Communication
Gateway Chapter

Micki Gamez
iHeart Radio
South Central Texas Chapter

iHeart Radio
Rhode Island Chapter

Rhonda Lapham
iHeart Radio
Rhode Island Chapter

Dr. Daliah Wachs
Southern Nevada

X102.3 FM
Palm Beach Area Chapter

Television
ABC7
Greater Bay Area Chapter

CW6
San Diego & Hawaii Chapter

Doug Dunbar
CBS11
North Texas Chapter

Lynda Martin
CW6
San Diego & Hawaii Chapter

Elex Michaelson
KABC-7
California Southland Chapter

KABC-7
California Southland Chapter

Nina Moine
WCCO-TV/CBS
Minnesota Chapter

Christine Pullara
WXIA-TV
Georgia Chapter

Melinda Spaulding
KRIV-Fox 26
Texas Gulf Coast Chapter

Jill Wagner
California Southland Chapter

Melissa Wilson
KRIV-TV 26
Texas Gulf Coast Chapter

WLKY
Kentucky & Southern Indiana Chapter

Shannon Wolfson
KXAN
South Central Texas Chapter

WCCO-TV/CBS
Minnesota Chapter

WXIA-TV Channel 11
Georgia Chapter

Manatt Phelps & Phillips LLP
California Southland Chapter

PwC
Silicon Valley & Monterey Bay Area Chapter

SanDisk
Silicon Valley & Monterey Bay Area Chapter

Silicon Valley Bank
Silicon Valley & Monterey Bay Area Chapter

South Pasadena Middle School
California Southland Chapter

Bronze: (5+ years of partnership)

A.C.E. Family Foundation
Long Island Chapter

Alaska Airlines
Washington & Alaska Chapter

BMC
North Texas Chapter

HFF
North Texas Chapter

Honored Hero Run
North Texas Chapter

Marge & Charles Schott
Tri-State Southern Ohio Chapter

Playtri
North Texas Chapter

Round Meadow Elementary School
California Southland Chapter

Thompson & Knight
North Texas Chapter

President’s Award
Recognizes a volunteer whose personal commitment and dedication inspires and motivates others to support our mission and help make Someday Today.

Christine Attia
Greater Bay Area Chapter

Board Citation Award
Corporation or organization whose ongoing commitment and dedication is worthy of national recognition.

American Electric Power
Central Ohio Chapter

KeyBank of Oregon
Oregon SW Washington Idaho Montana Chapter

Richard Loomis
SVP and CMO, Disney Channels Worldwide
California Southland Chapter

William Mason High School
Tri-State Southern Ohio Chapter

Chairman’s Advocacy Award
Volunteer, advocate or legislator recognized for support of LLS’s advocacy efforts.

Virginia Garner
California Southland Chapter

Senator Bill Ketron
Tennessee Chapter

BGen [ret] Steven A. Roser
North Texas Chapter

R. Keith Traster
North Texas Chapter

Chairman's Citation Award
Individual whose dedication to LLS is worthy of national recognition.

Marie Achatz
Long Island Chapter

Evelyn Bata, MD
National Capital Area

Jim Filiatlaurt, TCF Bank
Minnesota Chapter

Paul Fox
Illinois Chapter

Kerry Garnett
San Diego / Hawaii Chapter

Neil & Emily Kishter
National Capital Area Chapter

Ravindra Majeti, MD, PhD
Silicon Valley & Monterey Bay Area Chapter

Lois Markovich
Greater Bay Area Chapter

Kyle Mostransky
Long Island Chapter

Todd Oakes
Minnesota Chapter

William Patterson
Greater Bay Area Chapter

Lillian Pena
Greater Bay Area Chapter

Virginia Chapter

PuJ Rizvi
Palm Beach Area Chapter

Ruth Robinson
North Texas Chapter

Brint Ryan
North Texas Chapter

Melinda Spaulding
Texas Gulf Coast Chapter

Gary Thompson
South Central Texas Chapter

Amanda Tiede
National Capital Area Chapter

Nitasha Wallace (Premier Banks)
Minnesota Chapter

Daniel Weng
Central Ohio Chapter

Kevin Mumprey
Emmis Communication
Gateway Chapter

Dr. Daliah Wachs
Southern Nevada

X102.3 FM
Palm Beach Area Chapter

ABC7
Greater Bay Area Chapter

CW6
San Diego & Hawaii Chapter

Doug Dunbar
CBS11
North Texas Chapter

Lynda Martin
CW6
San Diego & Hawaii Chapter

Elex Michaelson
KABC-7
California Southland Chapter

KABC-7
California Southland Chapter

Nina Moine
WCCO-TV/CBS
Minnesota Chapter

Christine Pullara
WXIA-TV
Georgia Chapter
Research Grants

Specialized Center of Research
The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD 2013
Walter & Eliza Hall Institute of Medical Research
Jon Aster, MD 2013
Brigham and Women’s Hospital
John Byrd, MD 2011
The Ohio State University
William Carroll, MD 2014
New York University School of Medicine
Irene Ghobrial, MD 2014
Dana-Farber Cancer Institute
Helen Heslop, MD 2014
Baylor College of Medicine
Carl June, MD 2013
University of Pennsylvania
Thomas Kipps, MD, PhD 2014
University of California, San Diego
Jonathan Licht, MD 2013
University of Florida

Career Development Program (Scholars and Clinical Scholars)
The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Omar Abdel-Wahab, MD 2017* Memorial Sloan Kettering Cancer Center
Gregory Abel, MD 2013 Dana-Farber Cancer Institute
K Mark Ansel, PhD 2013 University of Pennsylvania
Sara Armenian, DO, MPH 2017 Beckman Research Institute of City of Hope
Uttiya Basu, PhD 2016 Columbia University Medical Center
Julie Blander, PhD 2015 Icahn School of Medicine at Mount Sinai
Patrick Brown, MD 2012 3 The Johns Hopkins University School of Medicine
Jan Burger, MD, PhD 2014 The University of Texas MD Anderson Cancer Center
Fernando Camargo, PhD 2016 Boston Children’s Hospital
Iain Cheeseman, PhD 2013 Whitehead Institute for Biomedical Research
Jerry Chipuk, PhD 2017 Icahn School of Medicine at Mount Sinai
Dipanjali Chowdhury, PhD 2015 Dana-Farber Cancer Institute
Tomasz Cierpicki, PhD 2017* University of Michigan
Christopher Cogle, MD 2013 University of Florida
Yali Dou, PhD 2013 University of Michigan
Benjamin Ebert, MD, PhD 2013 Brigham and Women’s Hospital
Thomas Fazzio, PhD 2015 University of Massachusetts Medical School
Benjamin Garcia, PhD 2016 Perelman School of Medicine at the University of Pennsylvania
Ramiro Garzon, MD 2016 The Ohio State University
Irene Ghobrial, MD 2017 Dana-Farber Cancer Institute
Andrei Goga, MD, PhD 2013 University of California, San Francisco
Jolanta Grembecka, PhD 2014 7 Icahn School of Medicine at Mount Sinai
David Guertin, PhD 2016 University of Massachusetts Medical School
Katharine Hsu, MD, PhD 2017* Memorial Sloan Kettering Cancer Center
Morgan Huse, PhD 2015 Memorial Sloan Kettering Cancer Center
John Koreth, MD, PhD 2014 5 Dana-Farber Cancer Institute
Ross Levine, MD 2013 6 Memorial Sloan Kettering Cancer Center
Ming Li, PhD 2015 Memorial Sloan Kettering Cancer Center
Ivan Maillard, MD, PhD 2014 University of Michigan
Ravindra Majeti, MD, PhD 2016 Leland Stanford Junior University
Constantine Mitsiades, MD, PhD 2017 Dana-Farber Cancer Institute
Golam Mohi, PhD 2014 SUNY Upstate Medical Center
Trista North, PhD 2017 Beth Israel Deaconess Medical Center
Ryoma Ohi, PhD 2014 Vanderbilt University Medical Center
Sophie Paczesny, MD, PhD 2015 Indiana University
Emmanuelne Passegué, PhD 2013 University of California, San Francisco
Jiaqi Peng, PhD 2015 Icahn School of Medicine at Mount Sinai
Stephen Sausville, MD 2015 Memorial Sloan Kettering Cancer Center
Joseph Scandura, MD, PhD 2014 Well Cornell Medical College
Mait Shanafelt, MD 2013 Mayo Clinic
Xiaobing Shi, PhD 2017* The University of Texas MD Anderson Cancer Center
Merav Socolovsky, MD, PhD 2013 University of Massachusetts Medical School
Daniel Starczynowski, PhD 2016 Cincinnati Children’s Hospital Medical Center
Kimberly Stegmaier, MD 2014 Dana-Farber Cancer Institute
Ulrich Steidl, MD, PhD 2015 Albert Einstein College of Medicine, Inc.
Enrico Tiacci, MD 2014 University of Perugia
Raoul Tines, MD, PhD 2015 Mayo Clinic Arizona
Wei Tong, PhD 2014 7 The Children’s Hospital of Philadelphia
David Traver, PhD 2013 University of California, San Diego
Christopher Vakoc, MD, PhD 2016 Cold Spring Harbor Laboratory
Ami Verma, MD 2013 Albert Einstein College of Medicine, Inc.
Hans-Guido Wendel, MD 2015 Albert Einstein College of Medicine, Inc.
Morgan Wicke, MD 2015 University of Alabama at Birmingham
Wenyi Wei, PhD 2014 Beth Israel Deaconess Medical Center
David Weinstock, MD 2014* Dana-Farber Cancer Institute
Hans-Guido Wendel, MD 2015 Memorial Sloan Kettering Cancer Center
Johnathan Whetstone, PhD 2015 Massachusetts General Hospital
Catherine Wu, MD 2015 Dana-Farber Cancer Institute
Xiaocun Yu, MD, PhD 2015 Beckman Research Institute of City of Hope
Chengcheng Zhang, PhD 2014 UT Southwestern Medical Center
Jing Zhang, PhD 2014 7 University of Wisconsin System
Xiaolan Zhao, PhD 2014 Memorial Sloan Kettering Cancer Center
Elina Zuniga, PhD 2013 University of California, San Diego

1 Dr. John Byrd is funded in part by Gerald Kafka & Rita Cavanaugh, Dough Baughman and Madeline & Stephen Arbinder.
2 Dr. Carl June is funded in part by Marc & Shani Weissbach.
3 Dr. Patrick Brown is funded in part by Thomas Moore.
4 Dr. Stephan Grupp is funded in part by HM Insurance Group.
5 Dr. David Porter is funded in part by Rita Cavanaugh & Gerald Kafka.
6 Dr. Ross Levine is fully funded by an anonymous donor.
7 Dr. Wei Tong is funded in part by the VWR Charitable Foundation and the Chartier Foundation.
Career Development Program (Special Fellows, Clinical Special Fellows and Fellows)

Spencer Alfred, PhD 2015
Leland Stanford Junior University
Burton Barnett, PhD 2015
University of California, San Diego
Cora Bergantinos, PhD 2015
Columbia University Medical Center
Shruti Bhatt, PhD 2017*
Boston Children’s Hospital
Sheng Cai, MD, PhD 2017*
Hospital
Hye Ji Cha, PhD 2017*
St. Jude Children’s Research Hospital
Ahmet Coskun, PhD 2016
California Institute of Technology
Leland Stanford Junior University
Hye Ji Cha, PhD 2017*
Boston Children’s Hospital
Spencer Alford, PhD 2015
(Memorial Sloan Kettering Cancer Center
Huan Chen, PhD 2017*
San Francisco University of California,
Nathan Vaisman.

10 Dr. Jonathan Eisenstein is fully funded by an anonymous donor.
11 Dr. Charles Gawad is funded in part by Thomas Moore.
12 Dr. Stanley Lee is fully funded by an anonymous donor.
13 Dr. Srividya Swaminathan is fully funded by an anonymous donor.
14 Dr. Robert Balarocchi is funded in part by Natan Vaisman.
15 Dr. Steven Grant is funded in part by the Breeden-Adams Foundation.

Dr. Matthew Matasar is funded in part by Gerald Eisenberg.

Dr. Charles Gawad is funded in part by Thomas Moore.
Dr. Srividya Swaminathan is fully funded by an anonymous donor.
Dr. Robert Balarocchi is funded in part by Natan Vaisman.
Dr. Steven Grant is funded in part by the Breeden-Adams Foundation.
Dr. Matthew Matasar is funded in part by Gerald Eisenberg.

Dr. Charles Gawad is funded in part by an anonymous donor.
Dr. Srividya Swaminathan is fully funded by an anonymous donor.
Dr. Robert Balarocchi is funded in part by Natan Vaisman.
Dr. Steven Grant is funded in part by the Breeden-Adams Foundation.
Dr. Matthew Matasar is funded in part by Gerald Eisenberg.

* Newly awarded or renewed grants in Fiscal Year 2017

The Leukemia & Lymphoma Society
Research Grants (continued)

Jolanta Grembecka, PhD 2016
University of Michigan
Timothy Hughes, MD, FRACP, FRCPA, MBBS 2017
South Australian Health & Medical Research Institute
Richard Jones, MD 2015
The Johns Hopkins University
School of Medicine
Emmanuel Katsanis, MD 2017
The University of Arizona
Michael Kharas, PhD 2017
Memorial Sloan Kettering Cancer Center
Yong-Mi Kim, MD, PhD, MPH 2015
San Francisco Medical Center
Andrew Kung, MD, PhD 2015
Columbia University
Noopur Raje, MD 2017
Memorial Sloan Kettering Cancer Center
Charles Mullighan, MBBS (Hons), MSc, MD 2017
St. Jude Children’s Research Hospital
Nikhil Munshi, MD 2016
Dana-Farber Cancer Institute
Markus Müschen, MD, PhD 2014
University of California, San Francisco
Smita Bhatia, MD, MPH 2016
Massachusetts General Hospital
Alain Rook, MD 2016
University of Alabama at Birmingham
Feyruz Rassool, PhD 2016
University of Maryland
Katya Revzani, MD, PhD 2015
The University of Texas MD Anderson Cancer Center
Alain Rook, MD 2016
University of Pennsylvania
James Rubenstein, MD, PhD 2014
University of California, San Francisco
Smita Bhatia, MD, MPH 2016
Memorial Sloan Kettering Cancer Center
Dr. Ari Melnick is funded in part in honor of Diane.

Dr. Markus Müschen is funded in part by Leon Borchers, Lisa Scheer Cone & Ed Cone.
Dr. John Timmerman is funded in part by Leon Borchers, Lisa Scheer Cone & Ed Cone.
Dr. Ari Melnick is funded in part by the Rich & Paula Lupon Family Foundation.
Dr. James Rubenstein is funded in part by the Rich & Paula Lupon Family Foundation.
Dr. Stephen Ansell is funded in part by an anonymous donor.
Dr. John Crispino is funded in part by the George L. Shields Foundation, Inc.
Dr. Stephen Dowdy is fully funded by the Dr. Ralph and Marian Falk Medical Research Trust.
Dr. John Crispino is funded in part by the Rich & Paula Lupon Family Foundation.
Dr. Ari Melnick is funded in part by the Paul E. Singer Foundation Innovation Grant in DLBCL.

Dr. Markus Müschen is funded
Cliniques de Montreal
Institut de Recherches
Tarik Moroy, PhD 2015
Weill Cornell Medical College
School of Medicine
The Johns Hopkins University
William Matsui, MD 2016
San Francisco Medical Center
Columbia University
Anjana Rao, PhD 2017
Massachusetts General Hospital
La Jolla Institute for Allergy and Immunology
Noopur Raje, MD 2017
Massachusetts General Hospital
Anjana Rao, PhD 2015
La Jolla Institute for Allergy and Immunology
Feyruz Rassool, PhD 2016
University of Maryland
Katya Revzani, MD, PhD 2015
The University of Texas MD Anderson Cancer Center
Alain Rook, MD 2016
University of Pennsylvania
James Rubenstein, MD, PhD 2014
University of California, San Francisco
San Diego - Health Sciences

Research Grants

Dr. John Timmerman is funded in part
Dr. James Rubenstein is funded in part
Dr. Ari Melnick is funded in part by Leon Borchers, Lisa Scheer Cone & Ed Cone.
Dr. John Crispino is funded in part by the Rich & Paula Lupon Family Foundation.
Dr. Stephen Ansell is funded in part by an anonymous donor.
Dr. John Crispino is funded in part by the George L. Shields Foundation, Inc.
Dr. Ari Melnick is funded in part by the Paul E. Singer Foundation Innovation Grant in DLBCL.

Dr. Ari Melnick is funded in part

Dr. Ari Melnick is funded in part by the Dr. Ralph and Marian Falk Medical Research Trust.
Dr. Ari Melnick is funded in part by the Paul E. Singer Foundation Innovation Grant in DLBCL.

Columbia University
Universitätsklinikum Mannheim
Academic Medical Center
Mignon Loh, MD 2015
University of California, San Francisco
Ivan Maillard, MD 2015
University of Michigan
William Matsui, MD 2016
The Johns Hopkins University
School of Medicine
Ari Melnick, MD 2015
Weill Cornell Medical College
Tanit Moroy, PhD 2015
Institut de Recherches Cliniques de Montreal

Translational Research Program: Renewal
Stephen Ansell, MD, PhD 2016
Mayo Clinic Rochester
Smita Bhatia, MD, MPH 2016
University of Alabama at Birmingham
John Crispino, PhD 2015
Northwestern University
Maria Figueroa, MD 2017
University of Michigan
Ronald Hoffman, MD 2017
Icahn School of Medicine at Mount Sinai
James Rubenstein, MD, PhD 2017
University of California, San Francisco
Ryan Wilcox, MD, PhD 2016
University of Michigan

MPN Challenge Grants
This program is run in partnership with the Myeloproliferative Neoplasm Research Foundation (MPNRF).
Nadia Carlesso, MD, PhD 2016
Indiana University School of Medicine
George Church, PhD 2016
Harvard Medical School
Camela Iancu-Rubin, PhD 2016
The Tisch Cancer Institute

Special Initiatives
Craig Crews, PhD 2017
Yale University
Steven Dowdy, PhD 2016
University of California, San Diego - Health Sciences
Ari Melnick, MD 2015
Well Cornell Medical College
Susan Parsons, MD 2015
Tufts Medical Center
Igor Roninson, PhD 2017
University of South Carolina

 Transforming CURES Initiative
John Crispino, PhD 2016
Northwestern University
Reuben Kapur, PhD 2016
Indiana University-Purdue University Indianapolis
Philip Koeffler, MD 2016
Cedars-Sinai Medical Center

IWMF Grants
This program is run in partnership with the International Waldenstrom's Macroglobulinemia Foundation (IWMF).
Christian Buske, MD 2017
University of Ulm
Madhav Dhodapkar, MBBS 2017
Yale University
Marcel Spaargen, PhD 2017
Academic Medical Center

* Newly awarded or renewed grants in Fiscal Year 2017
New Idea Award
A concept award that funds innovative approaches that may fundamentally change the understanding, diagnosis and/or treatment of blood cancers and related pre-malignant conditions.

Sara Buhrlage, PhD 2017*
Dana-Farber Cancer Institute

Aristotelis Tsirigos, PhD 2017*
University of California, San Francisco

Stephan Hedrick, PhD 2017*
University of California, San Diego

Nora Heisterkamp, PhD 2017*
Children’s Hospital Los Angeles

Heiko Konig, MD, PhD 2017*
Indiana University School of Medicine

Andrew Lane, MD, PhD 2017*
Dana-Farber Cancer Institute

Lev Silberstein, MD, PhD 2017*
Massachusetts General Hospital

Aristotelis Tsirigos, PhD 2017*
New York University

Vaiva Vezys, PhD 2017*
University of Minnesota

George Watts, PhD 2017*
The University of Arizona

Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Immunotherapy Initiative*
David Gottlieb, MB, MD, FRACP, FRCPA 2017*
University of Sydney

Ann Leen, PhD 2017*
Baylor College of Medicine

Ronald Levy, MD 2017*
Leland Stanford Junior University

Margaret Shipp, MD 2017*
Dana-Farber Cancer Institute

Rising Tide Foundation is funded in part by the Gregory J. Beaudry Family Foundation.

Research Portfolios

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Terry D. and Carol A. Agness Family Foundation.

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by Jonathan Bellobuono & Family and William McNitt.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Deborah and Randy Daniels and Tom Kelley.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Abbeville Family Partnership, S. Lori Brown, Charles Godchaux, Charles Foundation, Becky Godchaux, Dr. Larry and Leslie Nance, James and Judith Wilson and The Sarah Foundation.

Hodgkin Lymphoma Research Portfolio is funded in part by the AM Charity Fund.

Immunotherapy Initiative is funded in part by Greg Beaudry and Rising Tide Foundation.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by The Carlson Family Foundation, The Names Family Foundation and Niles Hushka/KLJ.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by American Expediting Company, Dr. Evelyn Bata and The John Wall Family Foundation.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by Jay and Susan Clark, Grand Chapter O.E.S. DC General Fund and Masonic and Eastern Star Home of the DC Charities, Kirk and Mindy Uhrlaub.

Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by the ACE Family Foundation (Mary & Michael Levine), Baltimores Orioles Foundation, Thomas and Agnes Carvel Foundation, Rhoda and David Chase Family Foundation, EFESTE Winery, Ella B. Cleveland Trust, Franklin American Mortgage Company, International Right of Way Association, Major League Baseball Players Trust, Team Bright Side, The Wawa Foundation.

Mission Portfolio is funded in part by Ping Y. Tai Foundation, Inc.

Weill Cornell Medicine Specialized Center of Research is funded in part by David J. Grais and Lisa A. Cutler, Scott and Cathy Zeilinger, Escher Foundation.

Quality of Life Research Portfolio is funded in part by The Hamill Family Trust and Hildegarde B. Becher Foundation.


### Endowment Funds

- Mary & Robert Bronstein Memorial Fund
- The Virginia Major Brooks Memorial Endowment Fund
- de Villiers Endowment Fund
- Thomas M. Ford Memorial Fund
- GlaxoSmithKline Foundation - Gertrude B. Elion Endowment Fund
- GlaxoSmithKline, Inc. Research Fund
- Jim Jacobs Leukemia Research Fund
- The Rachel Kudish Fund
- Jane Elissa/Charlotte Meyers Endowment Fund
- The Rae Endowment Fund (Ontario)
- Vrushali Ranadive Fellowship Fund
- Reich Endowment Fund
- The UFCW (Canada) Endowment Fund

### Partnerships

#### Therapy Acceleration Program Partnerships

- Acetylon Pharmaceuticals, Inc. Boston, MA
- Affirmed Therapeutics AG Heidelberg, Germany
- aGEN-X BV Breda, Netherlands
- BioTheryX, Inc. Chappaqua, NY
- Ivan Borrello, MD Johns Hopkins University
- Sidney Kimmel Comprehensive Cancer Center
- Celator Pharmaceuticals, Inc. Princeton, NJ
- Christopher Cogle, MD University of Florida
- Constellation Pharmaceuticals, Inc. Cambridge, MA
- Curis, Inc. Lexington, MA
- Institute for Applied Cancer Science The University of Texas MD Anderson Cancer Center
- Brian Druker, MD Oregon Health & Science University
- Mark Frattini, MD, PhD Memorial Sloan Kettering Cancer Center
- Irene Ghobrial, MD Dana-Farber Cancer Institute
- Anand Jillella, MD Emory University
- Kiadis Pharma NV Amsterdam, Netherlands
- Kite Pharma, Inc. Santa Monica, CA
- Holbrook Kohrt, MD, PhD & Ronald Levy, MD
- The Board of Trustees of the Leland Stanford Junior University
- OncoPep, Inc. North Andover, MA
- Daniel Pollyea, MD University of Colorado
- Yogen Saunthararajah, MD Cleveland Clinic
- Stemline Therapeutics, Inc. New York, NY
- Valor Biotherapeutics, LLC Dallas, TX

#### Medical & Scientific Advisors

- Steven Rosen, MD, FACP Beckman Research Institute of City of Hope Chair
- Stephen Ansell, MD, PhD Mayo Clinic Rochester, MN
- Leif Bergsagel Mayo Clinic Scottsdale, AZ
- Ravi Bhatia, MD University of Alabama at Birmingham
- Alan D’Andrea, MD Dana-Farber Cancer Institute
- Giulio Draetta, MD, PhD The University of Texas MD Anderson Cancer Center
- Philip Frost, MD, PhD
- Irene Ghobrial Dana-Farber Cancer Institute
- Catriona Jamieson University of California San Diego
- Larry Kwak, MD Beckman Research Institute of City of Hope
- Michelle LeBeau, PhD The University of Chicago
- Ross Levine, MD Memorial Sloan Kettering Cancer Center
- Jonathan Licht, MD University of Florida
- Alan List, MD H. Lee Moffitt Cancer Center & Research Institute
- Alexandra Mayes Birnbaum Peartree Communications, Inc.
- Susan O’Brien, MD University of California, Irvine
- Franklin O. Smith, III, MD Medpace

### Advisors

#### Therapy Acceleration Program Advisors

- A. Dana Callow, Jr., MBA Boston Millennia Partners Chair
- James Bradner, MD Dana-Farber Cancer Institute
- Joseph Catino, PhD Retired from Bayer
- C. Casey Cunningham, PhD Santé Ventures
- William Dalton, MD, PhD M2Gen
- Giulio Draetta, MD, PhD The University of Texas MD Anderson Cancer Center
- Iain W. Flinn, MD, PhD Tennessee Oncology
- Ross Levine, MD Memorial Sloan Kettering Cancer Center
- Ronald Levy, MD The Board of Trustees of the Leland Stanford Junior University
- Vern Norviel, JD Wilson Sonsini Goodrich & Rosati
- Susan M. O’Brien, MD University of California, Irvine
- J. Fred Pritchard, PhD Celerion

---

* Equity investment of $1,000,000 in Fiscal Year 2016

1 Ended service in December 2015
2 Started service in January 2016
The below listing is made up of individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

**Leadership Circle $1,000,000 and Above**

- **The Beer Store**
- **Burlington**
- **Cellgene Corporation**
- **Genentech, Inc.**
- **Gilead Sciences, Inc.**
- **The Harry T. Mangurian, Jr. Foundation**
- **Pfizer, Inc.**
- **The Olive Garden Italian Restaurant**
- **Pharmaceutical Companies**
- **Sarah Cannon Blood Cancer Network**
- **Takeda Pharmaceuticals USA, Inc. & Affiliates**
- **UFCW**
- **UFCW Canada/TUAC**

**Champion $500,000 – $999,999**

- **Barclays**
- **Bristol-Myers Squibb Company**
- **Lang/Stiglitz Family Fund**
- **The Norcross Foundation, Inc.**
- **The Paul E. Singer Foundation**
- **Novartis Pharmaceuticals Corporation**
- **The Paul E. Singer Foundation**
- **PVH**
- **Salesforce**
- **Anonymous (1)**

**Visionary $250,000 – $499,999**

- **AbbVie, Inc.**
- **Amgen, Inc.**
- **BMC**
- **Carter’s/OshKosh B’Gosh Discount Tires Co.**
- **Dr. Ralph & Marian Falk Medical Research Trust**
- **Elbit Systems of America**
- **Global Franchise Group – Great American Cookies® Marble Slab Creamery® MaggieMoo’s Ice Cream & Treatery®, Pretzelmania® and Hot Dog on a Stick®**
- **IHO P**
- **Perfumania**
- **Pharma - National SanDisk**
- **Stater Bros. Charities**
- **Teva Pharmaceuticals**
- **Walgreens**
- **Wells Fargo**
- **Anonymous (1)**

**Patron $100,000 – $249,999**

- **Alex and Alex**
- **James Allen**
- **Alto-Shaam, Inc.**
- **Alyssa’s Crew**
- **The Audrey Streadain Trust Dr. Evelyn Bata**
- **BDO**
- **Briggs Equipment**
- **Cancer Treatment Centers of America**
- **Charity Golf Outing**
- **Charles Esten’s Team Addie Julia A. Cogburn, MD**
- **The Coleman Foundation® Michael and Liz Copley®**
- **Cruise Planners, An American Express Representative**
- **EY**
- **F. M. Kirby Foundation, Inc.**
- **Farris Foundation**
- **FIS Foundation**
- **Ethel and Bernard Garil**
- **Goldman Sachs**
- **Imagine A Cure for Leukemia**
- **Incyte Corporation**
- **Industrial Alliance Insurance and Financial Services**
- **Juno Therapeutics, Inc.**
- **John Kellenyi**
- **Kite Pharma, Inc.**
- **KPMG**
- **Jeffrey Kushner**
- **Steven & Jeanie Lieblich**
- **Cristine and Timothy Linderfeller®**
- **Adrian Marantz and Corin Marantz in Memory of Olga The Marge & Charles J. Schott Foundation®**
- **Clyde McGregor and LeAnn Pedersen Pope**
- **Mercedes-Benz USA, LLC**
- **Morgan Stanley**
- **NSC Global**
- **Lyne and Greg O’Brien**
- **Orekawa Foundation**
- **Phillips Van Heusen**
- **PhRMA**
- **Donald Porteous**
- **PWC**
- **Nancy and Richard Rogers**
- **Jerry and Lois Rosenblum**
- **Nancy and Richard Rogers**
- **Jerry and Lois Rosenblum**
- **Faulkner Subaru**
- **Florida Cancer Specialists**
- **Garden City Turkey Trot Cindy and Brian Gavin**
- **GEICO WNY**
- **Generac Power Systems, Inc.**
- **Jonathan and Mindy Gray**
- **The Hamill Family Trust**
- **Hamilton E. James - James Family Foundation**
- **Hargrove**
- **Pete Harman**
- **The Harry and Jeanette Weinberg Foundation, Inc.**
- **Highland Park Village Marketing Group, LLC**
- **HM Insurance Group**
- **Hoffmann-La Roche Limited Infor Global Solutions**
- **J&D Development**
- **Jerry Oakey and Laura Randolph**
- **Pamela B. Katten Memorial Leukemia Research Foundation**
- **Johnson and Ashley Papelbon**
- **Penn Medicine**
- **Ping Y. Tai Foundation, Inc.**
- **PPG**
- **QEI Health Sciences Centre Foundation**
- **Rhenus Rock Hill Run & Ramble**
- **Riemer & Braunstein LLP**
- **Robert E. Gallagher Charitable Trust**
- **Edgar A. and Ruth E. Robinson**
- **The Salah Foundation**
- **In Memory of Virginia Salah**
- **Harold Salmanowitz Charitable Lead Annuity Trust**
- **Sammons Enterprises**
- **San Par Golf Tournament**
- **Sanofi US**
- **Starve Charitable Trust**
- **Linda Schwartzstein and Lee Goodwin®**
- **Sedano’s Supermarket**
- **Sempra & Southern California Gas Company**
- **John J. Silvesteri**
- **Solutionreach, Inc.**
- **Sorenson Legacy Foundation**
- **TerraGroup, Inc.**
- **Therakos, Inc.**
- **The Thomas J. Perkins and Gerd Perkins Foundation**
- **Timex**
- **Tracy and Ben Lange/Luke’s Fastbreaks**
- **Valenti Mid-Atlantic Management, LLC**
- **The Victor E. and Caroline E. Schulte Foundation**
- **Washingtonian Magazine**
- **The Wawa Foundation**
- **The Whitney Foundation**
- **The William Carter Company**

**Advocate $25,000 – $49,999**

- **21st Century Fox**
- **A.C.E. Family Foundation**
- **Agios Pharmaceuticals, Inc.**
- **Allstate Insurance Company**
- **Alverin M. Cornell Foundation**
- **American General Investments, LLC**
- **AMERICAN SYSTEMS**
- **AmTrust Bank - Division of New York Community Bank**
- **Madeline and Stephen Anbinder**
- **C.E. and Jean Andrews**
- **Anthem Blue Cross**
- **AT Corporation T/A IHOP**
- **AT&T**
- **Sidley Austin**
- **Baker Botts LLP**
- **Baltimore Orioles**
- **Baltimore Tour De Court**
- **In Memory of Rachel Minkove**
- **J&J Development**
- **Infor Global Solutions**
- **Hoffmann-La Roche Limited**
- **HM Insurance Group**
- **James Family Foundation**
- **Hamilton E. James - James Family Foundation**
- **Hargrove**
- **Pete Harman**
- **The Harry and Jeanette Weinberg Foundation, Inc.**
- **Highland Park Village Marketing Group, LLC**
- **HM Insurance Group**
- **Hoffmann-La Roche Limited Infor Global Solutions**
- **J&D Development**
- **Jerry Oakey and Laura Randolph**
- **Pamela B. Katten Memorial Leukemia Research Foundation**
- **Johnson and Ashley Papelbon**
- **Penn Medicine**
- **Ping Y. Tai Foundation, Inc.**
- **PPG**
- **QEI Health Sciences Centre Foundation**
- **Rhenus Rock Hill Run & Ramble**
- **Riemer & Braunstein LLP**
- **Robert E. Gallagher Charitable Trust**
- **Edgar A. and Ruth E. Robinson**
- **The Salah Foundation**
- **In Memory of Virginia Salah**
- **Harold Salmanowitz Charitable Lead Annuity Trust**
- **Sammons Enterprises**
- **San Par Golf Tournament**
- **Sanofi US**
- **Starve Charitable Trust**
- **Linda Schwartzstein and Lee Goodwin®**
- **Sedano’s Supermarket**
- **Sempra & Southern California Gas Company**
- **John J. Silvesteri**
- **Solutionreach, Inc.**
- **Sorenson Legacy Foundation**
- **TerraGroup, Inc.**
- **Therakos, Inc.**
- **The Thomas J. Perkins and Gerd Perkins Foundation**
- **Timex**
- **Tracy and Ben Lange/Luke’s Fastbreaks**
- **Valenti Mid-Atlantic Management, LLC**
- **The Victor E. and Caroline E. Schulte Foundation**
- **Washingtonian Magazine**
- **The Wawa Foundation**
- **The Whitney Foundation**
- **The William Carter Company**

* Denotes multi-year commitment

---

**Pharmaceutical Funding Legend**

- Patient Access
- Research
- Public Policy
- Campaign

---

The Leukemia & Lymphoma Society
Donors (continued)

Bank of America/Merrill Lynch  
Barbara Banke  
Joseph Baratta  
Baylor Scott & White Health  
BB&T Bank  
Gregory J. Beaudry Family Foundation  
Peggy Beckman  
Bert Smith & Co.  
Bloomberg  
BMo Harris Bank  
Bernie and Monica Boldt  
Bon Secours St Francis  
Booz Allen Hamilton  
Leon Borchers  
Michael Borchers  
Braman Miami  
Brayton Purcell, LLP  
Breeden-Adams Foundation  
Morris and Pamela Brown  
Joe & Cynthia Bruno  
April and Paul Buchheit  
Carlos Batista Foundation  
Carlson Family Foundation  
Capital One Bank  
CBRE – New England  
Charles McMurray Company  
The Charter Foundation  
City Line Construction  
Comcast  
Comedy Central  
Community Foundation of Collier County John C. Cona Fund  
Commerce Bank  
Community Foundation  
Sonoma County Community Medical Centers  
Beidre Cosby  
Cottrell Family Foundation  
CyberLock Inc.  
Dana Farber Cancer Institute  
Danford Foundation  
David Yurman  
Deloitte  
Dian Graves Owen Foundation  
DLA Piper LLP  
Don C. & Diane S. Lake Family  
Anna and Martin Donlon  
Marian Dozier  
Driscoll’s  
Edgar A. Thronson Foundation  
Edward G. & Kathryn E. Mader Foundation  
EFESTE Winery  
Ahmad El-Dardiry  
Eli Lilly & Co.  
Enterprise Holdings  
EZCORP  
Faulkner Nissan  
Jonathan Feldman  
Carl Fellbaum  
Raul and Jean-Marie Fernandez  
Fidelity Charitable Gift Fund  
Michael C. Fina  
Marilyn Flint  
Flushing Bank  
Fosx  
Franklin American Mortgage Company  
Martin and Sherry Franks  
Furniture Fair  
GAI Consultants  
Gateway Health Partners  
The Gatorade Company  
The Gaughen Management Group  
General Dynamics Information Technology  
Chris and Patricia Giannoulas  
Alison Gilmore  
Global Franchise Group  
David J. Grais and Lisa A. Cutler  
Greater Milwaukee Foundation, Inc.  
Eric and Rachel Green  
Thomas E. Hancock  
The Handelery Foundation  
HCA Foundation  
Hildegarde D. Becher Foundation Inc.  
Al Hill, Jr.  
J. Tomilson and Janine Hill  
Hitz Foundation  
David Hitz  
John and Kristin Hyland  
IBC Bank - Austin  
ICAP  
HeartMedia  
Ivie & Associates, Inc.  
J.T. Tai & Co. Foundation, Inc.  
Charles F. Jacobs  
Jefferies  
Jersey Mike’s Corporate Advertising Fund  
The Jim Jacobs Charitable Foundation  
John T. Gorman Foundation  
John Wall Family Foundation  
Johnson & Johnson  
Joseph & Catherine Johnson Family Foundation  
Just Give/Cisco  
K.S. Adams, Jr. Foundation  
Kaiser Permanente  
Kent’s Run  
The Keri Shull Team  
Kilroy Realty, LP  
Kritchman Family Foundation  
Landstone Companies  
Brenda Lavelle  
George Lee  
Leon Medical Centers  
Lights Out 4 Leukemia INC.  
The Lindquist Family Foundation  
2005  
Lunardi’s Market  
Luppe & Paula Luppen Family Foundation  
M.A. Mortenson Company  
Marsh Risk & Insurance Services  
Matthew and Kim Mausser  
MAXIMUS Foundation  
Merchandise Pickup Service, Inc.  
Merck & Company, Inc.  
Susanna L. Merriman In Loving Memory of Brian Merriman  
Metromont Corporation  
George Meza  
Miles & Stockbridge  
Robert Moore  
Thomas Moore  
John MorganFranklin Consulting  
NARS Cosmetics  
NASCAR Foundation  
The Netter Foundation  
Walter and Ellen Newsom  
Kenneth and Bonni Newton  
NFL Foundation  
Northrop Grumman  
Northside Hospital  
Northwestern Mutual  
Norton Rose Fulbright  
Papa John’s  
The Park Foundation  
Paul & Joan Rubschlager Foundation  
Peck School  
Peoples Natural Gas  
Pepco Holdings, Inc.  
David and Beverly Pfeifle  
PGF-Vista  
Publix Health Communications Group  
Rally Foundation for Childhood Cancer Research  
Miles J. Reidy  
Renate M. Dillon Trust  
Rendina Healthcare Real Estate Resource America  
The Rizvi Family  
Robert Graham Designs  
Melody Rogers  
ROMA Charitable Foundation  
Kathleen M. Rosenberg  
Lisa and Shawn Rosenzweig  
Jason Ryan  
Jeffrey D. Sachs  
Pat and Jeff Sachs  
Sarah Cannon HCA Midwest Health Blood Cancer Network  
Stephen Scherr  
Seattle Genetics, Inc.  
Security Service Federal Credit Union  
Bart Sichel  
Sidley Austin LLP  
Sandra Sinclair  
Paul Singer  
Southwestern Ohio Wendy’s  
St. Joseph’s/Candler  
St. Juste Management Corp.  
Thomas M. Stigers  
Monalst Sonsdor  
Subway Restaurants  
Swedish Health Services  
Sylvan Laureate Foundation  
Tigerlight Foundation  
Tommy Hilfiger Corp  
Trinity Industries  
Ultimate Software  
UNC REX Healthcare  
University of Miami Sylvester Comprehensive Cancer Center  
UPMC  
Wade Upton  
Valero  
Venable LLP  
Phil Venables  
Virginia Sheldon Jerome Foundation  
WVR Charitable Foundation (North Texas)  
Walmart  
The Warburg Pincus Society  
Washington Business Journal  
Ellen Weissberg  
Gloria Weissberg  
Mark Weissberg  
West New York Restoration of CT, Inc.  
WestOak Developments  
Terry Wilks  
William R. Rich Foundation  
Wool Farming and Processing  
WTOP Radio  
Adelaic W. Zabriskie  
Scott and Cathy Zeilinge  

Giving Circle  
$10,000-$24,999  
225 Fourth LLC  
Abacus Technical Services, LLC  
ABC 7/WJLA-TV  
Daniel Abeln  
Acadia Realty Limited Partnership  
Accenture  
Judith and Jon Ackerman  
Acqust Development  
Ann Milton Adams  
Samuel Adams  
Adobe  
AE Charitable Foundation  
AM Charity Fund  
AE Solutions  
AECOM Technology Corporation  
Aetna  
AIG  
Air Products Foundation  
Akin Gump Strauss Hauer & Feld, LLP  
Albrecht Family Foundation  
Alldridge Insurance  
Alfred R. Tobin Foundation  
Alliance Data  
Allied Solutions, LLC  
Almond & Company, LLC  
Alpha Omega Charitable Foundation  
AMC Charitable Fund  
Ameren  
American Direct Marketing Resources LLC  
American Electric Power  
American Expediting Company  
Ancira Auto Group  
Arthur Andersen  
Anonymous in Honor of Diane  
Anonymous in Honor of Jill Gillette  
Aon Risk Solutions  
AppLovin  
Aqueduct Technologies  
Ariad Pharmaceuticals, Inc.  
Charles and Kate Arnold  
Arthur J. Gallagher & Co.  
ARUP Laboratories  
Associated Credit Union  
Assurant Specialty Property  
Astellas Pharma US Inc.  
Astex Pharmaceuticals  

The Laverna Hahn Charitable Trust
Robert Maher
Magnum Power Products LLC
Albert Magid
Mack Madness, Inc.

The Lappin Foundation
Julia & Dennis Lincoln
Connie L. Lindsey
Kim and Jim Lites
Locke Lord LLP

Low Book Sales
Louie's Wine Dive
Low Book Sales

Lucy Martin and Family

Lumina Foundation

Luther Westside Volkswagen
Kent M. Lynch

M&T Bank

Mabee/Gumpert Philanthropic Fund
Mack Madness, Inc.
Margaret Madden
Albert Magid
Magnum Power Products LLC
Gerard and Joyce Magrini
Robert Maher
Major Hyundai
Major League Baseball Players Trust
Chuck Malk
Mallinckrodt, Inc. (RM)
Manatt Phelps & Phillips, LLP
Mariner Real Estate
Lois Markovich
The Marksman Company
Marsh Supermarkets, LLC
Bruce and Electra Martin
Marylo's Coffee

Mashkin Family Foundation
Masonic & Eastern Star Homes of the District of Columbia Charities
Massapequa Turkey Trot, Inc.
Massapequa Youth Lacrosse Club
MasterCard
Ken Matherne
MB Financial
Daniel McBride
Thomas McCarthy
Henry and Alta McCrary
Will & Emery McDermott
William McGee
Sean and Erin McGould
Jeff McGrath
McKesson Specialty Health
John & Kathy McKinley
McKinsey & Company
The McLelland Family Foundation
McNichols Family Foundation
William McNitt
Debbie and Danny McQuary
MD Anderson Cancer Center
Laurie Vest-Meador
MediaLocate, Inc.
MedImmune, LLC
MedSummit Solutions
Megan's Wings Inc.
Meiryer Foundation*

Otilia Melwani
Memorial Healthcare System
Alejandro and Evelyn Mendieta
Merchant Choice Payment Solutions
Mercy Health Partners - SWO

Merrill Lynch, Neat, Redpath, & Spaeath Wealth Management Group
Doug and Kersten Meyer
Massachusetts General Hospital Cancer Center
Miami Cancer Institute
Miami Parking Authority
Michael Sweig Foundation
Mike Woolf Farming Company
Milbank
Bruce Miller
Stephen Miller
Richard Mines
Mingledorf's Inc.

Sunil Mishra
Mitsubishi Hitachi Power Systems of America
Mobile Beacon
Lori Mody
Moglia Family Foundation
Molson Coors Canada
Monticello Spring Corporation
Patrick M. Moran
Donald Moreau
Kevin & Charity Moreland
Morgan Borszcz Consulting
Morgan, Lewis & Bockius LLP
Marcie and Jay Morrison
Tommy Morrison
Judge and Ali Moss
Motorola Solutions Foundation
Steve and Beverly Movius
Philip Moy
MSC Industrial Supply Co.
Mufiz and Chauhan Foundation
Bruce Murhead
Elizabeth M. Mungo
Adrian Munoz
Pamela and Byrne Murphy
Muy! Pizza Huts
Darryl Myers
n2grate Government Technology Solutions
Rick and Stacey Nadeau*
The Nagula Foundation INC

NAI Miami
Names Family Foundation
Larry and Leslie Nance
National Cooperative Services Corporation
National Neumonitoring
National Rural Utilities Cooperative Finance Corporation
Navarro Discount Pharmacies
Navarro Family Foundation
Nestle Purina PetCare Company
NetApp
New York Community Bank
Newmark Grubb Knight Frank

News4WOAI/Fox29/CW35
Nimble Storage
Niraj and Jill Shah/FCGF

NOCO
Nomura Securities International
North American Partners In Anesthesia
North Napa Rotary Club
North Sails
Northwell Health
 Northwest Hope Foundation

The Northwest Company, LLC
Nova Restoration
NPL Construction Company
NuStar Energy and The Greehy Family Foundation
NWN Corporation
Morgan O'Brien
Oppo Development
O'Donnell Honda
Office Environments International
Offshore Sailing School

The Ohio State University Comprehensive Center
Arthur G. James Cancer Hospital and Solove Research Institute
O'Keefe Lyons & Hynes, LLC
Pamela Oles

The Omer Foundation
Oncology Hematology Care, Inc. (OHC)

OneSource Distributors
Oregon Health & Sciences University
Peter O'Sullivan

Oxford Development Co.
Ostroff Associates
Pacific Service Credit Union
Pacific Union
Palanir
Jim and Gail Palmer
Park Place Dealerships Park
Place Dealerships
PathGroup, Inc.
The Paul B. Greetin and Beryl S. Greetin Foundation, Inc.
Pauline Allen Gill Foundation
Laura Taft Paulsen
Peake BMW
Lauren Pearson
Peck, Madigan, Jones & Stewart Inc.
Pegasus Builders, Inc.
Penn Color
Pennant Foods Corporation

DBA Wendy's
Pennock Acheson Nielsen
Devaney
Pennsylvania Wireless Association Inc.
Performance Automotive Network
Perfumania, Inc.
Scott and Whitney Perkins
Peter P. Bollinger Family Fund
Sheldon and Donita Petersen
Karen Peterson
Phase Foundation
Philadelphia Multiple Myeloma Networking Group
Hunter Philbrick
Dr. Tom Philbrick
Richard Phillips
Pietro's Restaurant Group
Pilot Travel Centers, LLC
Pivotal Software Inc.
Plaid Pantries, Inc.

Katie Plichta
Planned Systems International

Dale Putnam

PNC Foundation
Porsche of Annapolis
Ports America
PRA Health Sciences
Precision Manufacturing Co., Inc.
Presidio

Steven and Linda Priddy
Priority Physicians
Donald Proctor

Provision Health Alliance
The Pumping Stations, Inc.
Kevin Putnam
PVM (Tommy Hilfiger)
Quest Diagnostics
Ed Quinn

Quintiles

Quiznos Canada
Rabobank

Isicoff, Ragatz & Koenigsberg P.A.
Rambus

Russ & Norma Ramsey
RAST Foundation
Raynier Institute & Foundation
Red Robin
Reece Holbrook Win Anyway Foundation Inc.

JerSey Regan
Reilly Foods Company
Cambia and Brian Reinsborough

Republic Finance, LLC
James Resnick
Resolution Run to Kick Cancer Inc.
Reuben Foundation
Thomson Reuters

Rex 3, Inc.
The Rhoda and David Chase Family Foundation, Inc.
The Rhode Island Foundation
Richard & Terez Abatecola Foundation

* Denotes multi-year commitment

Pharmaceutical Funding Legend

Patient Access Research Public Policy Campaign

The Leukemia & Lymphoma Society 29
Donors (continued)

Nina Richardson
Rick Hendrick Chevrolet
Ritenburg Construction
Cindy and Steve Rigby
Juliana Riley
Riptide Property
Maintenance, LLC
Rising Capital Associates, LLC
Riverstone Resources LLC
RNDC South Carolina LLC
RoadID
Robert and Jenny Kottler/IBERIABANK
Robert H. Lyon Leukemia Foundation
Robert Half International, Inc.
Ruth E. Robinson
Rock Spring Contracting, LLC
The Roderick Seward, Flossie Radcliffe and Helen M. Galloway Foundation, Inc.
Bonnie Magid Roditti
Rogers Family Foundation
Bonnie Magid Roditti Foundation, Inc.
The Roderick Seward, Flossie Radcliffe and Helen M. Galloway Foundation, Inc.

Mike and Sue Smith
Melissa Smith
Kristie Smith
Dee Anna Smith
The Sleep Family
Small Army For A Cause, Inc.
Dee Anna Smith
Douglas and Phyllis Smith
Kristie Smith
Melissa Smith
Mike and Sue Smith
SMP
Sang pour sang asiatique
SAS
John Saunders
Savills Studley, Inc.
Sawnee EMC
Scheid Family Wines
Ivan Schlager
Robert Schlager
Robert C. Schmidt
Schneider Mitola, LLP
Jeff and Denise Schwindeman
Scott Stankavage Family Foundation of Triangle Community Foundation
Sedgwick
Mark Seltzer
Sempra Energy Foundation
Joe Sergi
Setton Farms
Settlement Alliance
Jerry Shae
The Shawner Family
Shearman & Sterling, LLP
Sherrard Kuzz LLP
Shulman, Rogers, Gandal, Pordy & Ecker L.P.
Bart Sichel
The Sidney, Milton and Leoma Simon Foundation
Judy and Albert Simon
Susan Simon
Barrie H. Simonson
Beth and Fred Singer
Siteman Cancer Center
Shade Tree Services Co.
Skadden, Arps, Slate, Meagher & Flom, LLP
Skanska
SL Green
The Sleep Family
Small Army For A Cause, Inc.
Dee Anna Smith
Douglas and Phyllis Smith
Kristie Smith
Melissa Smith
Mike and Sue Smith
SMP
Snelson’s Natural Gas
So Long to Leukemia
Anthony Soave
Shahan D. Soghikian
Sorenson Media, Inc.
South Eastern Development Association
Southern Proper Hospitality, LLC
Mark and Carol Spisak
Splug, Inc.
Sprout Loud, Media Networks
Sprouts Chula Vista
Gretchen Stangier
Phil Steel
Steele Resources, LLC
Mr. and Mrs. John M. Steele
Takeda Oncology
Todd and Diana Stiefel
Todd Reed McClintock Memorial Research Fund
Stringray Capital Partners I LLC
Sean Stout
Strategic Products and Services
Strategic Property Partners, LLC
Gabriel Stricker
Subaru of America, Inc.
Sugar Creek Packing Co.
Sullivan & Cromwell LLP
Patrick and Pam Sullivan
Sun Trust Bank
Sunesis Pharmaceutical
SunGard
Sunlight Supply
Suntrust Foundation
Susan G. Komen for the Cure
SunTrust Bank
Sunesis Pharmaceutical
SunGard
Sunlight Supply
Suntrust Foundation
Susan G. Komen for the Cure
Susan and John Thompson Family Fund
Swan & Legend
Bill Sweedler
Jerry Sweeney
Swing Fore The Cure
Timothy Talbot
Anne Tally
Rohan Taneja
Jeffrey Tannenbaum
Jack Tarditi
TAS Foundation
Tat Kwok
Tata America
Ann Taylor
Teachers and Tutus
Team Annie Rose Foundation
Tech Data
Techstar
Tee Off Against, Inc.
Teligistics, Inc.
Teneo Strategy LLC
Terakeet LLC
Terry D. & Carol A. Agness Family Foundation Trust
Terumo BCT
Texas Capital Bank
Texas Instruments
Texas Oncology
The Thalita N. Carlos & Chris M. Carlos Foundation
Larry Thayer
Thomas and Agnes Carvel Foundation
Judy and Michael H. Thomas
Thompson Habib & Denison Inc.
Tim and Sarah Jur Foundation
Tin Lizzy’s Cantina
Tishman Construction
Tishman Speyer
Title Associates
Tito’s Handmade Vodka
Tom & Virginia Jennaro Family Foundation, Inc.
Bruce Terrance
Dan Towtiss
Transcore
Transnational Bankcard, LLC
Transwestern
Larry and Nicole Treen
Lee Tepper and Dorine Real Trion
Gary and Angela Trovato
Troy Savings Bank Music Hall
True North Family Foundation
TrueNorth
Kevin and Kristen Tu
TurningPoint Global Solutions, LLC
Renée & Larry Tversky
Brian Tyl
Jean and Wallace Tyner
U.S. Chamber of Commerce Foundation
UBS Financial Services Inc.
UCSF Benioff Children’s Hospital
UCFW Local 75
Uhlig LLC
Mark Uhlig
Kirk and Mindy Uhrshaub
Ulm Family Foundation
The Ultimate Software Group, Inc.
Unanet
The University of Kansas Cancer Center
United Properties Brokerage LLC
United Security Bank
United Way of Greater Milwaukee
United Way of San Antonio and Bexar County
The University of Michigan
United Way of Greater Milwaukee
United Way of San Antonio and Bexar County

William G. Pomeroy Foundation
William J. Shaw Family Foundation
Williams & Connolly LLP
Wills Towers Watson
James Wilson
Winston & Strawn LLP
World Care
Washington Prime Group
Yahoo Employee Foundation
Yogurtland
Eric, Tamara, and Nicholas Yollick Youman, Madero & Fasano
Zappos.com
The Zenith Insurance Company
Zodiac Inflight Innovations
Joseph Zvesper
Anonymous (?)
## Top Campaign Fundraisers

Schools that have raised more than $25,000, individuals who have raised more than $50,000 or companies/teams that have raised more than $100,000 to support LLS’s mission.

### $5k Club 2016

<table>
<thead>
<tr>
<th>Blood Busters: Funding Blood Cancer Cures</th>
<th>Colton’s Army</th>
<th>The Glew Family</th>
<th>Danielle Johnston</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bloomberg</td>
<td>Jason Cowan</td>
<td>Steve Golden</td>
<td>Jonathan M. Eisenberg &amp; We B Stronga</td>
</tr>
<tr>
<td>Brad Blumenfeld</td>
<td>Jennie Crandal</td>
<td>Dan Goodrich</td>
<td>Megan Jones</td>
</tr>
<tr>
<td>Dr. Ann A. Bockrath</td>
<td>Darris Crandal</td>
<td>Grandma’s Marathon Team - MN Chapter</td>
<td>Michelle Jordan-Berndt</td>
</tr>
<tr>
<td>Kim Boerman</td>
<td>Credit Suisse</td>
<td>Maria Grasso</td>
<td>Just Cure It</td>
</tr>
<tr>
<td>Abigail Boldt</td>
<td>Mathew Cromar</td>
<td>Mark Greco</td>
<td>Anne Kacmaric Johnson</td>
</tr>
<tr>
<td>Mira Bolton</td>
<td>DeAnna Crosby</td>
<td>Bobby Green</td>
<td>Ari Kahan</td>
</tr>
<tr>
<td>Jon Bonnell</td>
<td>Michelle Crossland</td>
<td>Mary Guzek, DMD</td>
<td>Homaira Karimi</td>
</tr>
<tr>
<td>Lexie Boudreaux</td>
<td>Cycle For Life</td>
<td>Katie Daily</td>
<td>Katie Pilchta &amp; Team Dream and Do</td>
</tr>
<tr>
<td>Carla Brems</td>
<td>Dare to Care</td>
<td>Nolana Myka Daoust</td>
<td>Betsy Katten</td>
</tr>
<tr>
<td>Brent Hagye’s Campaign Team</td>
<td>Michael G. Dash</td>
<td>Dare to Care</td>
<td>Rebecca Kellum</td>
</tr>
<tr>
<td>Derek Brock</td>
<td>David Stone &amp; Team JAMEN</td>
<td>Joseph DeSabella</td>
<td>Annie Kelly</td>
</tr>
<tr>
<td>Jennifer Brody</td>
<td>Genevieve Dean</td>
<td>Tennessee</td>
<td>Michael King</td>
</tr>
<tr>
<td>John Brockbank III</td>
<td>Tori Deatherage</td>
<td>Jennifer Heckler</td>
<td>Kiven, Kotler, Lieberman, Fox, Joffe, Goldschmidt &amp; Kepes</td>
</tr>
<tr>
<td>Michael Brooks</td>
<td>Stephanie DeFreese</td>
<td>Heidi Netzley &amp; Team Happy Feet</td>
<td>Dr. Ramesh Kolluru</td>
</tr>
<tr>
<td>Kristin Brotherton</td>
<td>Joseph DeSabella</td>
<td>Christen Heye</td>
<td>Robert Kottler</td>
</tr>
<tr>
<td>Morris Brown</td>
<td>Surrender P. Chillon</td>
<td>Sean Hieter</td>
<td>Scott J. Kurinsky</td>
</tr>
<tr>
<td>Craig Browning</td>
<td>Brian Diaz</td>
<td>Leslie Hitleman</td>
<td>Victoria Landau</td>
</tr>
<tr>
<td>William Buckley</td>
<td>Christina Diehl</td>
<td>Holli Hines Easton</td>
<td>James Lau</td>
</tr>
<tr>
<td>Brittoni Burdett</td>
<td>Discount Tire</td>
<td>Chrissy Hixon</td>
<td>Chris Lee</td>
</tr>
<tr>
<td>Ian Burnett</td>
<td>Kathy Disher</td>
<td>Brandon Hoehn</td>
<td>Trenton Leftingwell</td>
</tr>
<tr>
<td>Burlington Des Lacs Elementary School</td>
<td>Disney Team MA Chapter</td>
<td>Carolyn Hoover</td>
<td>Donald Lewis</td>
</tr>
<tr>
<td>Amanda Bush†</td>
<td>Brian Domingos</td>
<td>Greg Horine</td>
<td>David Liotta</td>
</tr>
<tr>
<td>Ace Calvert</td>
<td>Matthew Donaldson</td>
<td>Greg Hostetler</td>
<td>Danny Loenthal</td>
</tr>
<tr>
<td>Robert “Spider” Cantley</td>
<td>Tam Driscoll&quot;</td>
<td>Lisa Howell</td>
<td>Lu Lunatics Powered by Kailie’s Krew and Bryan Cave</td>
</tr>
<tr>
<td>TJ Caplinger</td>
<td>Dr. Greg Eberhart</td>
<td>David O’Connell</td>
<td>Matt Mackowiak</td>
</tr>
<tr>
<td>Kelsey Carr</td>
<td>Brittany A. Edelman</td>
<td>Lynne O’Brien</td>
<td>Marion Elementary School</td>
</tr>
<tr>
<td>Carter’s Rich Catan</td>
<td>Elex Michaelson &amp; Team</td>
<td>Rick Ostroff</td>
<td>Joanna Marker</td>
</tr>
<tr>
<td>Daniel Chianese</td>
<td>“We’re All In It Together”</td>
<td>Angie Palomo</td>
<td>Kraig Marking</td>
</tr>
<tr>
<td>Elizabeth Childers</td>
<td>David Ervin</td>
<td>Partners For A Cure</td>
<td>Roshan Markusman</td>
</tr>
<tr>
<td>Jim Chrisman†</td>
<td>Vikki Evans</td>
<td>Alex Pascual</td>
<td>Mason City School District - Mason High School</td>
</tr>
<tr>
<td>Christina Diehl</td>
<td>Beth Faiman, PhD</td>
<td>Learn about</td>
<td>Patrick McAndrew</td>
</tr>
<tr>
<td>Chad Clardy</td>
<td>Geri Farr</td>
<td>LLS Advocates</td>
<td>Michael J. McBride</td>
</tr>
<tr>
<td>Andrew Clark</td>
<td>Katherine Ferguson</td>
<td>Leesa Media</td>
<td>Vanessa McDonald</td>
</tr>
<tr>
<td>Michael Clark</td>
<td>Mary Figura</td>
<td>LLS Advocates</td>
<td>Erin McFarland</td>
</tr>
<tr>
<td>M. Preston Clarke</td>
<td>Valerie Fiordilino</td>
<td>LLS Advocates</td>
<td>Joseph McKenna &amp; Team Lily</td>
</tr>
<tr>
<td>Greg Clary</td>
<td>Michael Fisher</td>
<td>LLS Advocates</td>
<td>John McNeill</td>
</tr>
<tr>
<td>Clearwater Middle School</td>
<td>Matthew Filinchbaugh</td>
<td>LLS Advocates</td>
<td>Simon Tipper-McWhorther</td>
</tr>
<tr>
<td>Julia Cogburn, MD</td>
<td>Florida Power &amp; Light</td>
<td>LLS Advocates</td>
<td>Atilia Melwani</td>
</tr>
<tr>
<td>April Cohen</td>
<td>Sam Forrest</td>
<td>LLS Advocates</td>
<td>Dr. Jeffrey Menashe</td>
</tr>
<tr>
<td>Brianne Cohen</td>
<td>Christopher G. Foy</td>
<td>LLS Advocates</td>
<td>Amy Merrill</td>
</tr>
<tr>
<td>Ron Cohn</td>
<td>Richard Gaff</td>
<td>LLS Advocates</td>
<td>Jake Merrill</td>
</tr>
<tr>
<td>Michael Colen</td>
<td>Geico</td>
<td>LLS Advocates</td>
<td>LLS Advocates</td>
</tr>
<tr>
<td>Tom Collins</td>
<td>Jessica Gianulas and Natalie Woodruff</td>
<td>LLS Advocates</td>
<td>LLS Advocates</td>
</tr>
<tr>
<td><strong>Pharmaceutical Funding Legend</strong></td>
<td>LLS Advocates</td>
<td>LLS Advocates</td>
<td>LLS Advocates</td>
</tr>
</tbody>
</table>

† Denotes National Man & Woman of the Year

‡ Denotes multi-year commitment

** Denotes National Man Woman of the Year All Star Alum

<table>
<thead>
<tr>
<th>R  Research</th>
<th>C  Campaign</th>
<th>PA  Patient Access</th>
<th>PP  Public Policy</th>
<th>C  Campaign</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Peggy Abbott* Charles Anderson* Thomas Angelo* Renza Moscattelli Baker* Frances Barker* Nicholas Bartlone* Norman and Betty Bertiaux*
Bill Beatle Memorial Fund (Alberta) Violet Blakeley* Erwin Brandt* James Brewster, III John Cahill (In Memory of Dorothy J. Cahill) Eric Carlson* Dawn Carr
Megan Clemens Steve and Shannon Clifford (In Memory of Mary Pat Clifford) Emma Connor* Helen Cook* Rodger and Lori Coon* Nellie Coudare* Dolores Dare* Millard C. Davis* Peggy and Margaret Dupaquier* Alison Edwards Theresa Eichorn* John Eidel* Mark Elansky* Christina Elliott* Seymour Falk (In Memory of Margot Cole) Daryl Fallin* Anthony Farmer Nellie Fishman* Deborah Fletcher* Anita Foster* Timothy Frates Bella Frutkin*


** Denotes National Man & Woman of the Year All Star Alum

* Deceased

---

Lisa Pektor Perfumania, Inc. Leslie Pierce Matthew Priddy, MD Eric A. Pullen Gayle Coleman Rader The RALLY Campaign Rampart High School Rawn William’s Team Joseph Reigadas Re-Remission For Ryan Caroline Rice Ride For Ron Riders of the Storm Shannon Ridley Joe Tedesco Team Terminate Cancer Team United Terumo BCT Christine Thayer Katie Thomas Brandon Thompson Dalton Thompson Jason Thompson

Toni Anna Hull & Hull’s Heroes Gary Trovato Jessica Tursi Nahid Usmani, MD Joe Vermillion Joe Vicari** Virtual Nerd Runs for a Cure Lindsay Vogelman Waddell & Reed/Ivy Investments Ryan Wade


Thomas Williams, Jr. Leigh Ann Woodall Michael Woolf Mark Yoffe, MD You Gotta Believe Joshua Zeidner, MD Logan Zinman ** Legacy Circle (continued)
Independent Auditors’ Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2016, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2016, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Report on Summarized Comparative Information We have previously audited LLS’s consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated October 21, 2015. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2015 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

November 2, 2016
## Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2016 (with comparative amounts at June 30, 2015) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents (note 1)</td>
<td>$18,596</td>
<td>52,897</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>2,906</td>
<td>6,049</td>
</tr>
<tr>
<td>Legacies and contributions receivable, net (note 5)</td>
<td>17,244</td>
<td>8,989</td>
</tr>
<tr>
<td>Investments (note 3)</td>
<td>168,293</td>
<td>137,941</td>
</tr>
<tr>
<td>Fixed assets, net (note 7)</td>
<td>16,946</td>
<td>14,826</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$223,985</td>
<td>220,702</td>
</tr>
</tbody>
</table>

|                |         |         |
| **Liabilities and Net Assets**       |         |         |
| Liabilities:                              |         |         |
| Accounts payable and accrued expenses   | $13,655 | 16,975  |
| Deferred revenue (note 6)               | 12,916  | 17,802  |
| Awards and grants payable (note 2)      | 60,451  | 69,335  |
| Co-Pay assistance payable (note 2)      | 13,469  | 14,465  |
| Other long-term liabilities (note 1)    | 1,638   | 1,441   |
| **Total liabilities**                   | 102,129 | 120,018 |

Commitments and contingencies (notes 2 and 9)

Net assets (note 4):

- Unrestricted: 84,178 72,848
- Temporarily restricted: 34,241 24,146
- Permanently restricted: 3,437 3,690

**Total net assets**: 121,856 100,684

**Total liabilities and net assets**: $223,985 220,702

*See accompanying notes to consolidated financial statements.*
## Consolidated Statement of Activities

*The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2016 (with summarized totals for the year ended June 30, 2015) (In thousands)*

### Operating revenue

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2016</th>
<th>Total 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$235,036</td>
<td>23,279</td>
<td>64</td>
<td>258,839</td>
<td>259,429</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(26,348)</td>
<td>—</td>
<td>—</td>
<td>(26,348)</td>
<td>(24,606)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>208,688</td>
<td>23,279</td>
<td>64</td>
<td>232,491</td>
<td>234,823</td>
</tr>
<tr>
<td>Co-pay contributions</td>
<td>—</td>
<td>46,379</td>
<td>—</td>
<td>46,379</td>
<td>43,000</td>
</tr>
<tr>
<td>Legacies</td>
<td>5,159</td>
<td>2,787</td>
<td>—</td>
<td>7,946</td>
<td>10,157</td>
</tr>
<tr>
<td>Donated services and media (note 6)</td>
<td>11,175</td>
<td>—</td>
<td>—</td>
<td>11,175</td>
<td>9,864</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>1,347</td>
<td>5</td>
<td>—</td>
<td>1,352</td>
<td>1,904</td>
</tr>
<tr>
<td>Net assets released from restrictions (note 2):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>44,673</td>
<td>(44,673)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>18,102</td>
<td>(18,062)</td>
<td>(40)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total operating revenue</td>
<td>289,144</td>
<td>10,175</td>
<td>24</td>
<td>299,343</td>
<td>299,748</td>
</tr>
</tbody>
</table>

### Operating expenses (note 6 and 10)

*Program services:*

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2016</th>
<th>Total 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>54,691</td>
<td>—</td>
<td>—</td>
<td>54,691</td>
<td>71,540</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>89,209</td>
<td>—</td>
<td>—</td>
<td>89,209</td>
<td>95,526</td>
</tr>
<tr>
<td>Public health education</td>
<td>42,881</td>
<td>—</td>
<td>—</td>
<td>42,881</td>
<td>36,249</td>
</tr>
<tr>
<td>Professional education</td>
<td>15,373</td>
<td>—</td>
<td>—</td>
<td>15,373</td>
<td>16,829</td>
</tr>
<tr>
<td>Total program services</td>
<td>202,154</td>
<td>—</td>
<td>—</td>
<td>202,154</td>
<td>220,144</td>
</tr>
</tbody>
</table>

*Supporting services:*

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2016</th>
<th>Total 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>27,553</td>
<td>—</td>
<td>—</td>
<td>27,553</td>
<td>31,006</td>
</tr>
<tr>
<td>Fund raising</td>
<td>44,749</td>
<td>—</td>
<td>—</td>
<td>44,749</td>
<td>46,205</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>72,302</td>
<td>—</td>
<td>—</td>
<td>72,302</td>
<td>77,211</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>274,456</td>
<td>—</td>
<td>—</td>
<td>274,456</td>
<td>297,355</td>
</tr>
</tbody>
</table>

| Change in net assets from operating activities | 14,688 | 10,175 | 24 | 24,887 | 2,393 |
| Foreign currency translation adjustment | (30) | (80) | — | (110) | (530) |
| Net decrease in fair value of investments (note 3) | (4,157) | — | — | (4,157) | (1,585) |
| Net assets transferred and reclassified (note 1) | 829 | — | (277) | 552 | — |
| Change in net assets | 11,330 | 10,095 | (253) | 21,172 | 278 |

### Net Assets

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2016</th>
<th>Total 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>72,848</td>
<td>24,146</td>
<td>3,690</td>
<td>100,684</td>
<td>100,406</td>
</tr>
<tr>
<td>End of year</td>
<td>$84,178</td>
<td>34,241</td>
<td>3,437</td>
<td>121,856</td>
<td>100,684</td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
## Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2016 (with comparative totals for the year ended June 30, 2015) (In thousands)

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Total</th>
<th>Direct Donor Benefit Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2016</td>
<td>2015</td>
</tr>
<tr>
<td>Awards and grants (note 2)</td>
<td></td>
<td>40,011</td>
<td>53,717</td>
</tr>
<tr>
<td>Therapy acceleration program (note 2)</td>
<td></td>
<td>9,343</td>
<td>13,503</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td></td>
<td>1,299</td>
<td>430</td>
</tr>
<tr>
<td>Co-pay assistance (note 2)</td>
<td></td>
<td>40,030</td>
<td>41,804</td>
</tr>
<tr>
<td>Co-pay processing fees</td>
<td></td>
<td>3,375</td>
<td>4,581</td>
</tr>
<tr>
<td>Donated services and media (note 6)</td>
<td></td>
<td>3,698</td>
<td></td>
</tr>
<tr>
<td>Salaries</td>
<td></td>
<td>11,175</td>
<td>9,864</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 8)</td>
<td></td>
<td>1,299</td>
<td></td>
</tr>
<tr>
<td>Occupancy (note 9)</td>
<td></td>
<td>40,030</td>
<td>41,804</td>
</tr>
<tr>
<td>Insurance</td>
<td></td>
<td>3,375</td>
<td>4,581</td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
<td>3,698</td>
<td></td>
</tr>
<tr>
<td>Travel and meetings</td>
<td></td>
<td>11,175</td>
<td>9,864</td>
</tr>
<tr>
<td>Printing, advertising, and supplies</td>
<td></td>
<td>12,826</td>
<td>13,888</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td></td>
<td>1,285</td>
<td>1,709</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td></td>
<td>40,030</td>
<td>41,804</td>
</tr>
<tr>
<td>Professional fees</td>
<td></td>
<td>3,375</td>
<td>4,581</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td>3,698</td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td></td>
<td>12,826</td>
<td>13,888</td>
</tr>
<tr>
<td>Total expenses</td>
<td></td>
<td>54,691</td>
<td>42,881</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Cash Flows

*The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2016 (with comparative amounts for the year ended June 30, 2015) (In thousands)*

<table>
<thead>
<tr>
<th>Cash flows from operating activities:</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td>$21,172</td>
<td>278</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net decrease in fair value of investments</td>
<td>4,157</td>
<td>1,585</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>6,450</td>
<td>5,780</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
<td>(445)</td>
<td>126</td>
</tr>
<tr>
<td>Change in long-term liability</td>
<td>197</td>
<td>(425)</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>3,143</td>
<td>(687)</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
<td>(7,810)</td>
<td>(2)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(3,320)</td>
<td>(1,844)</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(4,886)</td>
<td>(8,943)</td>
</tr>
<tr>
<td>Awards and grants payable</td>
<td>(8,884)</td>
<td>(14,866)</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
<td>(996)</td>
<td>2,233</td>
</tr>
<tr>
<td>Net cash provided by (used in) operating activities</td>
<td>8,778</td>
<td>(21,231)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cash flows from investing activities:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchases of fixed assets</td>
<td>(8,570)</td>
<td>(4,002)</td>
</tr>
<tr>
<td>Purchases of investments</td>
<td>(238,736)</td>
<td>(36,640)</td>
</tr>
<tr>
<td>Sales of investments</td>
<td>204,227</td>
<td>85,999</td>
</tr>
<tr>
<td>Net cash (used in) provided by investing activities</td>
<td>(43,079)</td>
<td>45,357</td>
</tr>
<tr>
<td>Net (decrease) increase in cash and cash equivalents</td>
<td>(34,301)</td>
<td>24,126</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>52,897</td>
<td>28,771</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of year</td>
<td>$18,596</td>
<td>52,897</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
1] Organization and Summary of Significant Accounting Policies

A] Organization
The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer, and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

B] Principles of Consolidation
The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its fifty six chapters in the United States, and LLS’s not for profit affiliates, The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), Beat AML (BAML) and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS.

C] Tax-Exempt Status
LLS, LLSRF, LLSRP and PPCS qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

BAML is a single member limited liability company and is a disregarded pass-through entity. Accordingly, all revenue and expenses are included in LLS. Income of BAML is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) consistent with LLS.

LLS and PPCS recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities recognizing any unrelated business income tax liability for the years ended June 30, 2016 and 2015.

D] Estimates
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, allowance for uncollectible accounts, allocation of expenses, and valuation of donated services and media. Actual results could differ from those estimates.

E] Risks and Uncertainties
LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is contributions by the general public. Accordingly, LLS’s operations are dependent upon individual contributions, that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2016 and 2015 was funded by nine and eight donors, respectively.

F] Summarized Financial Information
The consolidated financial statements are presented with 2015 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2015 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2015 consolidated financial statements from which the summarized information was derived.

G] Subsequent Events
LLS evaluated subsequent events after the balance sheet date of June 30, 2016 through November 2, 2016, which was the date the consolidated financial statements were issued.

On August 23, 2016, LLS received a payment triggered by a change in control clause within a Therapy Acceleration Program (TAP) agreement. LLS funded several phases of research and clinical trials as part of this agreement. In addition to the payment received, LLS may receive additional payments contingent on the advancement of drug FDA approval and commercialization.

H] Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

- **Unrestricted net assets**: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.
- **Temporarily restricted net assets**: Consist of funds that are restricted by donors for a specific time period and/or purpose.
- **Permanently restricted net assets**: Consist of funds that contain donor imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds is recorded as temporarily restricted net assets and is released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board approved spending policy (note 4).

I] Foreign Currency Translation
LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2016

J) Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

K) Contributions, Grants and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

L) Donated Services
LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense (note 6).

M) Donated Media
LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSA’s (note 6).

N) Cash Equivalents
Cash equivalents consist of short term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

O) Investments
Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

P) Fixed Assets and Depreciation
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

Q) Other Long-Term Liabilities
Other long-term liabilities represent LLS’s liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 8) and straight-line rent of office leases (note 9).

R) Professional Fees
Professional fees included in the consolidated financial statements principally include professional fund-raising fees, contracted software development, and legal and auditing fees.

S) Reclassifications
Certain reclassifications of 2015 amounts have been made to conform to the 2016 presentation.

2) Research and Co-Pay Assistance Program
LLS has various activities that are utilized to carry out its mission as presented below:

Research

Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi year grant commitments of $56,541,000 at June 30, 2016, which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $60,451,000 and $69,335,000 at June 30, 2016 and 2015, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $450,000 and $3,104,000 as of June 30, 2016 and 2015, respectively, have been netted against awards and grants expense.

TAP is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug enabling studies and clinical stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $10,214,000 and $20,842,000 at June 30, 2016 and 2015, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$34,812</td>
</tr>
<tr>
<td>2018</td>
<td>$17,298</td>
</tr>
<tr>
<td>2019 and thereafter</td>
<td>$14,645</td>
</tr>
<tr>
<td>Total</td>
<td>$66,755</td>
</tr>
</tbody>
</table>
Co-Pay Assistance Program
Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. Accordingly, LLS has recognized $8,960,000 and $7,254,000 in temporarily restricted revenue as of June 30, 2016 and 2015, respectively, for which the corresponding expense is not recognized until the subsequent fiscal year as patients are approved in the program. The Co-Pay Assistance payable of $13,469,000 and $14,465,000 has been established based on approved patient applications received through June 30, 2016 and 2015, respectively. At June 30, 2016, temporarily restricted net assets include $8,960,000 received in 2016, which are available for expenditure and are intended to be awarded in fiscal 2017.

The following summarizes the activities of the Co-Pay Assistance program in 2016 and 2015 (in thousands).

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$7,254</td>
<td>11,707</td>
</tr>
<tr>
<td>Grant commitments</td>
<td>46,379</td>
<td>43,000</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>(40,030)</td>
<td>(41,804)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>(4,843)</td>
<td>(5,649)</td>
</tr>
<tr>
<td>Amounts available for expenditures in the next year</td>
<td>$8,960</td>
<td>7,254</td>
</tr>
</tbody>
</table>

3) Investments
The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2016 and 2015 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$58,704</td>
<td>58,704</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>36,228</td>
<td>36,228</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>2,032</td>
<td>2,032</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>22,466</td>
<td>22,466</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>International equity</td>
<td>20,406</td>
<td>20,406</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>10,429</td>
<td>10,429</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Real estate</td>
<td>5,293</td>
<td>5,293</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Commodities</td>
<td>2,996</td>
<td>2,996</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total investments reported at net asset value</td>
<td>$158,554</td>
<td>158,554</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$18,544</td>
<td>18,544</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income (mutual fund)</td>
<td>27,599</td>
<td>27,599</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Short duration fixed income (mutual fund)</td>
<td>30,222</td>
<td>30,222</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>2,285</td>
<td>2,285</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>7,577</td>
<td>7,577</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>International equity</td>
<td>5,355</td>
<td>5,355</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>223</td>
<td>223</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Real assets</td>
<td>5,638</td>
<td>5,638</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total investments reported at net asset value</td>
<td>$97,443</td>
<td>97,443</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

In 2016, LLS transitioned from a traditional Investment custodian to an Outsourced Chief Investment Officer. In this process, LLS liquidated its investment portfolio and re-invested all funds. Investment expenses of $560,000 and $866,000 have been netted against the net decrease in fair value of investments for the years ended June 30, 2016 and 2015, respectively. The unrealized gains (losses) were $3,513,000 and ($4,851,000) for the years ended June 30, 2016 and 2015, respectively.

LLS’s alternative investments are diversified across two investment strategies, as follows:

1. Multi strategy hedge funds – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.
2. Long/short equities – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.
These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 45-95 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2016 and 2015, the following table summarizes the redemption provisions for those investments reported at net asset value (in thousands):

<table>
<thead>
<tr>
<th>Redemption period</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarterly</td>
<td>$6,003</td>
<td>38,075</td>
</tr>
<tr>
<td>Annual</td>
<td>3,736</td>
<td>2,423</td>
</tr>
<tr>
<td>Total</td>
<td>$9,739</td>
<td>40,498</td>
</tr>
</tbody>
</table>

In accordance with ASU 2015 10, Technical Corrections and Improvements, LLS removed $6,965,000 as of June 30, 2015 from investments reported at net asset value (or its equivalent) and included these amounts in Level 1 to correct the fair value hierarchy table.

As of June 30, 2016 and 2015, LLS has no unfunded commitments on its alternative investments.

### 4] Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2016 and 2015 (in thousands):

<table>
<thead>
<tr>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporarily restricted</td>
<td>Permanently restricted</td>
</tr>
<tr>
<td>Time restrictions</td>
<td>$272</td>
</tr>
<tr>
<td>Research</td>
<td>19,377</td>
</tr>
<tr>
<td>Patient service</td>
<td>5,367</td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>8,960</td>
</tr>
<tr>
<td>Other</td>
<td>265</td>
</tr>
<tr>
<td>Total</td>
<td>$34,241</td>
</tr>
</tbody>
</table>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2016 and 2015 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2016 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$3,086</td>
<td>3,690</td>
<td>6,776</td>
</tr>
<tr>
<td>Investment (loss) income</td>
<td>(164)</td>
<td>64</td>
<td>(100)</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>280</td>
<td>–</td>
<td>280</td>
</tr>
<tr>
<td>Reclassifications</td>
<td>–</td>
<td>(277)</td>
<td>(277)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(240)</td>
<td>(40)</td>
<td>(280)</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$2,962</td>
<td>3,437</td>
<td>6,399</td>
</tr>
</tbody>
</table>

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2015 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$3,164</td>
<td>3,575</td>
<td>6,739</td>
</tr>
<tr>
<td>Investment income</td>
<td>61</td>
<td>43</td>
<td>104</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>82</td>
<td>72</td>
<td>154</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(221)</td>
<td>–</td>
<td>(221)</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$3,086</td>
<td>3,690</td>
<td>6,776</td>
</tr>
</tbody>
</table>

### 5] Legacies and Contributions Receivable

LLS’s legacies and contributions receivable at June 30, 2016 and 2015 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$10,723</td>
<td>7,111</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>7,272</td>
<td>2,413</td>
</tr>
<tr>
<td>After 5 years</td>
<td>50</td>
<td>575</td>
</tr>
<tr>
<td>Subtotal</td>
<td>18,045</td>
<td>10,099</td>
</tr>
<tr>
<td>Less: Allowance for uncollectible accounts</td>
<td>(169)</td>
<td>(614)</td>
</tr>
<tr>
<td>Discount to present value (1.5% to 5.0%)</td>
<td>(632)</td>
<td>(496)</td>
</tr>
<tr>
<td>Total</td>
<td>$17,244</td>
<td>8,989</td>
</tr>
</tbody>
</table>

As of June 30, 2016, 65% of gross legacies and contributions receivable were from two funding sources.
6) Deferred Revenue, Donated Services and Media

During 2013, LLS received a $20,000,000 grant with the contractual agreement to be utilized for research that is jointly identified by the grantor and LLS. At June 30, 2016 and 2015, the unexpended balances of the grant of $1,145,000 and $4,504,000, respectively, are included in deferred revenue. Revenue under this grant is expected to be recognized over the next year, as expenses are incurred. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated services</td>
<td>$ 2,867</td>
<td>4,468</td>
</tr>
<tr>
<td>Donated media</td>
<td>8,308</td>
<td>5,396</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$11,175</strong></td>
<td><strong>9,864</strong></td>
</tr>
</tbody>
</table>

7) Fixed Assets, Net

Fixed assets at June 30, 2016 and 2015 consist of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$ 1,434</td>
<td>1,109</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>3,397</td>
<td>2,629</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>39,706</td>
<td>31,829</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$44,537</strong></td>
<td><strong>35,567</strong></td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(27,591)</td>
<td>(20,741)</td>
</tr>
<tr>
<td><strong>Fixed assets, net</strong></td>
<td><strong>$16,946</strong></td>
<td><strong>14,826</strong></td>
</tr>
</tbody>
</table>

8) Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $1,827,000 and $1,858,000 for the years ended June 30, 2016 and 2015, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). Expenses under the 457 Plans approximated $10,000 for the year ended June 30, 2015. There were no expenses incurred for the year ended June 30, 2016. The assets of the 457 Plans are included in investments in the accompanying consolidated balance sheet and amounted to approximately $1,405,000 and $1,490,000 at June 30, 2016 and 2015, respectively. The liabilities of the 457 Plans are included in other long term liabilities in the accompanying consolidated balance sheet and amounted to approximately $1,374,000 and $1,380,000 at June 30, 2016 and 2015, respectively.

9) Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through March 31, 2031, and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities. On September 15, 2015, LLS entered into a 15 year lease for 41,868 square feet of space for its National Office beginning March 2016. The lease terms provide for one year of rent abatement. Free rent periods, tenant improvement allowances, and charges are accounted for on a straight-line basis over the life of the lease.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ 6,008</td>
<td>5,584</td>
<td>4,560</td>
<td>4,071</td>
<td>3,670</td>
<td>15,286</td>
<td>$ 39,179</td>
</tr>
</tbody>
</table>

10) Joint Costs Allocation

For the years ended June 30, 2016 and 2015, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$ 13,901</td>
<td>15,294</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>2,076</td>
<td>1,152</td>
</tr>
<tr>
<td>Public health education</td>
<td>5,117</td>
<td>3,179</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$21,094</strong></td>
<td><strong>19,625</strong></td>
</tr>
</tbody>
</table>
National Leaders

Chairman of the Board
James H. Davis, PhD, JD
Palm Beach Gardens, FL

Vice Chair
Elizabeth J. (Betsy) Clark
ACSW
Saugerties, NY

Secretary/Treasurer
Kenneth M. Schwartz
EY
New York, NY

At Large
Donald R. Proctor
Cisco Systems
San Jose, CA

Board of Directors
James A. Beck
Hefren-Tilston, Inc.
Butler, PA

William G. Behnke
The Behnke Group
San Antonio, TX

Jorge L. Benitez
CEO Accenture NA, retired
Coral Gables, FL

Peter Bennett Brock
Brock Development Corp.
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Scott A. Carroll, JD
Jackson Lewis
Cincinnati, OH

William S. Dalton, MD, PhD
M2Gen
Tampa, FL

Graciela C. Eleta
Eleta Consulting, Inc.
Guaynabo, PR

Bernard H. Garil
Delray Beach, FL

Francie Heller
Heller Advisory
New York, NY

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Richard M. Jeaneret
EY
New York, NY

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Ralph E. Lawson
Baptist Health South Florida
Coral Gables, FL

Michelle LeBeau, PhD
University of Chicago
Chicago, IL

Gilles B. Legault
Global Legal Affairs
Montréal, Quebec, Canada

Connie L. Lindsey
Northern Trust
Chicago, IL

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Bart Sichel
Burlington Stores
Florence Township, NJ

Frank O. Smith, III, MD
Medpace
Cincinnati, OH

Kathryn C. Vecellio
Vecellio Group
Palm Beach, FL

Louise G. Warner
Chagrin Falls, OH

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society
Louis J. DeGennaro, PhD
President & CEO

Danielle Gee
Chief of Staff

Andrew S. Coccari, Jr.
Executive Vice President
Chief Product Officer

Rosemarie Loffredo
Executive Vice President
Chief Financial & Administrative Officer

Alice O’Rourke
Executive Vice President
Chief Development Officer

Mark Roithmayr
Executive Vice President
Chief Relationship Officer

The Leukemia & Lymphoma Society of Canada
Shelagh Tippet-Fagyas
President
Canadian Operations
cure leukemia, lymphoma, hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.